

Combining cycloisomerization with trienamine catalysis: A regiochemically flexible enantio- and diastereoselective synthesis of hexahydroindoles

Venkaiah Chintalapudi, Elizabeth A. Galvin, Rebecca L. Greenaway and Edward A. Anderson*

Chemistry Research Laboratory, 12 Mansfield Road, Oxford, OX1 3TA, U.K.

Email: edward.anderson@chem.ox.ac.uk

Contents

1. EXPERIMENTAL	
1.1 General Experimental Considerations	2
1.2 General Procedures	3
1.3 Experimental procedures and characterization of compounds	5
1.3.1 <i>Synthesis of dienal 3a</i>	5
1.3.2 <i>Cycloaddition reactions of dienal 3a</i>	8
1.3.3 <i>Synthesis of dienals 4a-d and 8a</i>	23
1.3.4 <i>Cycloaddition reactions of dienals 4a-d</i>	32
1.3.5 <i>Synthesis of dienals 3b and 4e</i>	42
1.3.6 <i>Double stereodifferentiating cycloaddition reactions of dienals 3b and 4e</i>	51
2. REFERENCES	57
3. NMR SPECTRA	58
3.1 <i>Intermediates in the synthesis of dienal 3a</i>	58
3.2 <i>Cycloaddition products of dienal 3a</i>	63
3.3 <i>Intermediates in the synthesis of dienals 4a-d and 8a</i>	79
3.4 <i>Cycloaddition products of dienals 4a-d</i>	98
3.5 <i>Intermediates in the synthesis of dienals 3b and 4e</i>	107
3.6 <i>Double stereodifferentiating cycloaddition products of dienals 3b and 4e</i>	123

1. EXPERIMENTAL

1.1 General Experimental Considerations

Nuclear Magnetic Resonance Spectroscopy: ^1H NMR spectra were acquired on Bruker DRX500, AVII500 (500 MHz, with cryoprobe) or AVIII400 (400 MHz) spectrometers and were referenced to residual non-deuterated solvent peaks in CDCl_3 ($\delta = 7.26$) or C_6D_6 ($\delta = 7.16$). Chemical shifts (δ_{H} and δ_{C}) are reported in parts per million (ppm) with signal splittings recorded as singlet (s), doublet (d), triplet (t), quartet (q), quintet (quin), and multiplet (m); app = apparent. Coupling constants (J) are measured to the nearest 0.1 Hz and are presented as observed. ^{13}C NMR spectra were obtained on Bruker AVII500 (126 MHz, with cryoprobe) or AVIII400 (101 MHz) spectrometers and were referenced to solvent peaks in CDCl_3 ($\delta = 77.16$). Where diastereomeric mixtures are formed, data is given for the major diastereomer, unless specified otherwise.

Mass Spectrometry: Low-resolution mass spectra (m/z) were recorded on a Waters LCT Premier EX mass spectrometer, using electrospray ionization (ESI). High-resolution mass spectra (HRMS) were recorded by the Departmental Mass Spectrometry Service, University of Oxford on a Bruker MicroTOF (resolution = 5000 FWHM) using electrospray ionisation (ES^+). The parent ion $[\text{M}]^+$, $[\text{M}+\text{H}]^+$ or $[\text{M}+\text{Na}]^+$ is calculated to 4 decimal places from the molecular formula, and all values are within a tolerance of 5 ppm.

Infrared Spectroscopy: Absorption spectra were obtained in CHCl_3 as solvent on a Bruker Tensor 27 FT-IR spectrometer. The sample was prepared as a thin film on a diamond/ZnSe PIKE Miracle ATR module. Wavelengths of maximum absorbance (ν_{max}) are quoted in wavenumbers (cm^{-1}). Only selected, characteristic IR absorption data are provided for each compound.

Specific rotations: Optical rotations were recorded on a Perkin Elmer 241 or 341 polarimeter with a path length of 1 dm (using the sodium D line, 589 nm). Specific rotations ($[\alpha]_D$) are reported in units of 10^{-1} deg $\text{cm}^2 \text{ g}^{-1}$. Concentrations are reported in g/100 mL. Temperatures are reported in $^\circ\text{C}$ (typically 25 $^\circ\text{C}$).

Chromatography: Flash chromatography refers to normal phase column chromatography on silica gel using a head pressure of N_2 , using either Merck Geduran[®] Silicagel 60 (40 - 63 μm) or Macherey-Nagel Silica 60 M (40 - 63 μm). Thin-layer chromatography was performed on Merck Kieselgel 60 F₂₅₄ plates with visualization by ultraviolet light (254 nm) and/or heating the plate after staining with vanillin or KMnO_4 . High performance liquid chromatography (HPLC) was performed on an Agilent 1200 Series running in normal phase under UV detection using a ZORBAX RX-SIL (150 mm x 4.6 mm ID) as the analytical column. Chiral analysis was carried out using DAICEL CHIRALPAK-IA, IB or IC (250 mm x 4.6 mm ID).

Materials: Unless otherwise stated, all reactions were carried out in oven-dried glassware under an atmosphere of argon, using anhydrous reaction solvents. Et_2O , CH_2Cl_2 , THF and toluene were dried over activated alumina before use. All other commercially available reagents and solvents were either used as received, and/or dried and purified before use using standard procedures. Petroleum ether refers to the fraction of light petroleum ether boiling at 40-60 $^\circ\text{C}$ unless stated otherwise.

1.2 General Procedures

General Procedure A: Mitsunobu Reaction

DIAD (1.3 equiv.) was added dropwise to a stirred solution of alcohol (1.0 equiv.), triphenylphosphine (1.5 equiv.) and methyl tosylcarbamate (1.2 equiv.) in THF (3 mL / mmol of alcohol) at 0 °C. The reaction mixture was stirred at rt overnight, then it was filtered and concentrated. The residue was taken up in petroleum ether / Et₂O (1:1, 10 mL / mmol of alcohol), stirred for 5 min, then filtered and concentrated. The residue was once again taken up in petroleum ether / Et₂O (1:1, 10 mL/mmol of alcohol), stirred for 5 min, filtered, and the filtrate concentrated. Purification by flash chromatography afforded the product.

General Procedure B: Carbamate deprotection of sulfonamide carbamates

To a solution of the carbamate (1.0 equiv.) in MeOH (10 mL / mmol carbamate) was added K₂CO₃ (2.0 equiv.). The reaction mixture was stirred for 5 h at RT, then it was concentrated to a volume of approximately 5 mL. The mixture was then added to NH₄Cl (10 mL / mmol carbamate), and extracted with EtOAc (3 × 10 mL / mmol carbamate). The combined organic layers were dried (MgSO₄), filtered and concentrated. Purification by flash chromatography afforded the product.

General Procedure C: Copper(II)-catalysed enynamide formation

According to the procedure of Hsung et al.¹ To a mixture of sulfonamide (1.0 equiv.), CuSO₄·5H₂O (0.2 equiv.), 1,10 phenanthroline (0.4 equiv.) and K₃PO₄ (2.0 equiv.) was added a solution of bromoalkyne (1.4 equiv.) in toluene (2 mL / mmol sulfonamide). The reaction mixture was stirred at 70 °C for 15 h before being allowed to cool to RT. The reaction mixture was filtered through Celite, eluting with Et₂O, and the filtrate was concentrated. Purification by flash chromatography afforded the ynamide.

General Procedure D: Cs₂CO₃ promoted synthesis of dichloroenamides

According to the procedure of Anderson et al.² To a stirred suspension of amide (1.0 equiv.) and Cs₂CO₃ (3.0 equiv.) in DMF (0.75 mL / mmol amide), at 50 °C, was added trichloroethylene (3.0 equiv.) dropwise over ten minutes. The resulting mixture was stirred at 50 °C for 2 h. Upon cooling to rt, the mixture was partitioned between EtOAc and water, the organic layer was separated and further washed with water (x 3). The organic layer was dried (Na₂SO₄), filtered, and concentrated. Purification by flash chromatography afforded the enamide.

General Procedure E: Synthesis of ynamides using phenyllithium

According to the procedure of Trost et al.³ and Anderson et al.² To a stirred solution of 1,2-dichloroenamide (1.0 equiv.) in THF (10 mL / mmol of enamide), at -78 °C was added phenyllithium (2.0 M solution in dibutyl ether, 2.2 equiv.) dropwise over 10 minutes. The reaction mixture was stirred at -78 °C for 1 h, after which time iodomethane (1.2 equiv.) was added. The solution was allowed to warm to rt and stirred for 1 h. The reaction mixture was quenched with water and the aqueous layer extracted with Et₂O (x 2). The combined organic extracts were dried (MgSO₄), filtered, and concentrated. Purification by flash chromatography afforded the product ynamide.

General Procedure F: Palladium-catalysed cycloisomerization

According to the procedure of Anderson *et al.*⁴ To a solution of enynamide (1.0 equiv.) in toluene (6.5 mL / mmol of enynamide) was added *N,N*-bis-(benzylidene)ethylenediamine (0.05 equiv.) and Pd(OAc)₂ (0.05 equiv.). The reaction mixture was stirred at 60 °C for 30 min, then cooled to rt and concentrated. Purification by flash chromatography afforded the product.

General Procedure G: TBS-deprotection of silyloxy amidodienes

To a solution of diene (1.0 equiv.) in THF (20 mL / mmol of diene) was added TBAF (1.3 equiv.). The reaction mixture was stirred at rt for 2 h, before being diluted with EtOAc, filtered through a silica plug and concentrated. Purification by flash chromatography afforded the product.

General Procedure H: Parikh-Doering Oxidation

Et₃N (5.0 equiv.), DMSO (7.0 equiv.) and SO₃·py (3.0 equiv.) were added to a solution of alcohol (1.0 equiv.) in DCM (6 mL / mmol of alcohol) at 0 °C. The solution was stirred at 0 °C for 2 h before being quenched with pH 7 phosphate buffer (20 mL). The mixture was extracted with EtOAc (3 x 20mL), washed with brine (2 x 20mL), dried (MgSO₄) and concentrated. Purification by flash chromatography afforded the product.

General Procedure I: Dess-Martin Oxidation

To a solution of alcohol (1.0 equiv.) in CH₂Cl₂ at 0 °C was added Dess-Martin periodinane (1.2 equiv.), and then the reaction was allowed to warm to rt and stirred for 1.5 h. After this time, NaHCO₃ (sat., aq.) was added and the layers were separated. The aqueous layer was extracted with CH₂Cl₂, and the combined organic extracts were dried (Na₂SO₄), filtered, and concentrated. Purification by flash chromatography provided the aldehyde.

General Procedure J: Trienamine-catalysed Diels-Alder cycloaddition with nitrostyrenes and olefinic azlactones

To a vial containing catalyst **10** (0.2 equiv.), benzoic acid (0.2 equiv.) and the respective dienophile (1.0 equiv.) was added the amidodiene (1.4 equiv.) in toluene (5 mL / mmol of amidodiene). The resulting mixture was stirred at RT for 2-5 h, then (ethoxycarbonylmethylene)triphenylphosphorane (0.15 mmol, 1.5 equiv.) was added. The reaction was then stirred overnight, then it was concentrated and the residue directly purified by flash chromatography.


General Procedure K: Trienamine-catalysed Diels-Alder cycloaddition with olefinic oxindoles and lactones

To a vial containing catalyst **10** (0.2 equiv.), benzoic acid (0.2 equiv.) and the respective dienophile (1.0 equiv.) was added the amidodiene (1.5 equiv.) in toluene (5 mL / mmol of amidodiene). The resulting mixture was stirred at RT for 2-6 h before being diluted with EtOAc, filtered through a silica plug, and concentrated.


1.3 Specific experimental procedures and characterization of compounds

1.3.1 Synthesis of dienal **3a**

Dienal **3a** was synthesized according to the following Scheme:




Methyl but-3-en-1-yl(tosyl)carbamate, **S1**




Prepared by General Procedure A using but-3-en-1-ol (1.20 ml, 1.00 g, 13.9 mmol). The resulting crude material was purified by flash chromatography (petroleum ether / Et₂O (9:1)) to give **S1** as a colourless oil (3.50 g, 12.4 mmol, 89%). **IR** (thin film, ν_{max} / cm⁻¹) 2980, 1728, 1691, 1450, 1355, 1293, 1185, 767; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 7.82 (2H, d, *J* = 8.4 Hz, TsH), 7.29 (2H, d, *J* = 8.4 Hz, TsH), 5.77 (1H, ddt, *J* = 17.1, 10.2 and 6.9 Hz, H3), 5.12-5.05 (2H, m, H4), 4.02-3.76 (2H, m, H1), 3.67 (3H, s, CO₂Me), 2.47 (2H, dd, *J* = 14.7 and 7.3 Hz, H2), 2.41 (3H, s, TsCH₃); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 152.7, 144.5, 136.5, 134.0, 129.2, 128.2, 117.5, 53.6, 46.5, 34.3, 21.5; **HRMS** (ES⁺) calc. for C₁₃H₁₈O₄NS [M+H]⁺ 284.0951; found 284.0950.

N-(But-3-en-1-yl)-4-methylbenzenesulfonamide, S2




Prepared by General Procedure **B** using methyl but-3-en-1-yl(tosyl)carbamate **S1** (4.20 g, 14.8 mmol). The resulting crude material was purified by flash chromatography (petroleum ether / Et₂O (4:1)) to give **S2** as a colourless oil (3.01 g, 13.4 mmol, 90%); **1H NMR** (400 MHz, CDCl₃) δ_H 7.74 (2H, d, *J* = 8.5 Hz, TsH), 7.30 (2H, d, *J* = 8.5 Hz, TsH), 5.61 (1H, ddt, *J* = 17.0, 10.5 and 7.0 Hz, H3), 5.07-4.98 (2H, m, H4), 4.63 (1H, br s, NH), 3.00 (2H, app q, *J* = 6.5 Hz, H1), 2.42 (3H, s, TsCH₃), 2.18 (2H, app q, *J* = 7.0 Hz, H2); **13C NMR** (101 MHz, CDCl₃) δ_C 143.6, 137.1, 134.3, 129.9, 127.2, 118.2, 42.2, 33.7, 21.7; **HRMS** (ES⁺) calc. for C₁₁H₁₆O₂NS [M+H]⁺ 226.0896; found 226.0896. Data identical to literature values.⁵

N-(But-3-en-1-yl)-N-(4-((tert-butyldimethylsilyl)oxy)but-1-yn-1-yl)-4-methylbenzenesulfonamide, 5a



Prepared by General Procedure **C** using sulfonamide **S2** (1.83 g, 8.12 mmol, 1.0 equiv.) and ((4-bromobut-3-yn-1-yl)oxy)(tert-butyl)dimethylsilane (2.57 g, 9.75 mmol, 1.2 equiv.). The resulting crude material was purified by flash chromatography (petroleum ether / EtOAc (95:5)) to give **5a** as a colourless oil (2.76 g, 6.78 mmol, 84%); **IR** (thin film, ν_{max} / cm⁻¹) 2929, 2222, 1364, 1171, 1105; **1H NMR** (400 MHz, CDCl₃) δ_H 7.76 (2H, d, *J* = 8.0 Hz, TsH), 7.32 (2H, d, *J* = 8.0 Hz, TsH), 5.70 (1H, ddt, *J* = 17.0, 10.2 and 6.8 Hz, H8), 5.11-4.99 (2H, m, H9), 3.66 (2H, t, *J* = 7.1 Hz, H1), 3.31 (2H, t, *J* = 7.3 Hz, H6), 2.47 (2H, t, *J* = 7.1 Hz, H2), 2.43 (3H, s, TsCH₃), 2.35 (2H, dd, *J* = 14.8 and 6.9 Hz, H7), 0.87 (9H, s, Si-Bu), 0.04 (6H, s, SiMe₂); **13C NMR** (101 MHz, CDCl₃) δ_C 144.3, 134.6, 133.7, 129.6, 127.6, 117.4, 73.7, 67.5, 62.1, 50.7, 32.0, 25.8, 22.8, 21.5, 18.2, -5.4; **HRMS** (ES⁺) calc. for C₂₁H₃₄O₃NSi [M+H]⁺ 408.2023; found 408.2021.


(Z)-2-(3-((tert-Butyldimethylsilyl)oxy)propylidene)-3-methylene-1-tosylpyrrolidine, S3



Prepared by General Procedure **F** using ynamide **5a** (1.02 g, 2.50 mmol). The crude material was purified by flash chromatography (petroleum ether / EtOAc (95:5)) to give **S3** as a colourless oil (0.91 g, 2.23 mmol, 89%); **IR** (thin film, ν_{max} / cm⁻¹) 2928, 2857, 1357, 1166, 1092; **1H NMR** (400 MHz, CDCl₃) δ_H 7.67 (2H, d, *J* = 6.5 Hz, TsH), 7.23 (2H, d, *J* = 7.8 Hz, TsH), 6.03 (1H, t, *J* = 6.7 Hz, H3), 5.22 (1H, s, H9), 4.66 (1H, s, H9), 3.76 (2H, t, *J* = 6.1 Hz, H1), 3.53 (2H, t, *J* = 6.6 Hz, H6), 2.75 (2H, app q, *J* = 6.5 Hz, H2), 2.41 (3H, s, TsCH₃), 1.83 (2H, t, *J* = 6.4 Hz, H7), 0.91 (9H, s, Si-Bu), 0.07 (6H, s, SiMe₂); **13C NMR** (101 MHz, CDCl₃) δ_C


143.8, 143.1, 137.5, 135.9, 129.5, 127.7, 118.3, 103.9, 62.6, 48.5, 33.3, 29.0, 25.9, 21.6, 18.3, -5.2; **HRMS** (ES⁺) calc. for C₂₁H₃₄O₃NSSi [M+H]⁺ 408.2023; found 408.2021.

(Z)-3-(3-Methylene-1-tosylpyrrolidin-2-ylidene)propan-1-ol, S4



Prepared by General Procedure **G** using **S3** (508 mg, 1.25 mmol). The resulting crude material was purified by flash chromatography (petroleum ether / EtOAc (1:1)) to give the title compound **S4** as a colourless oil (350 mg, 1.19 mmol, 96%); **IR** (thin film, ν_{max} / cm⁻¹) 3450, 2925, 1090, 1162, 1348, 1597; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 7.68 (2H, d, *J* = 8.3 Hz), 7.24 (2H, d, *J* = 8.3 Hz), 5.98 (1H, t, *J* = 7.7 Hz, H3), 5.26 (1H, t, *J* = 2.4 Hz, H9), 4.69 (1H, t, *J* = 2.2 Hz, H9), 3.85 (2H, t, *J* = 6.0 Hz, H1), 3.55 (2H, t, *J* = 7.4 Hz, H6), 2.84 (2H, app. q, *J* = 6.8 Hz, H2), 2.41 (3H, s, TsCH₃), 1.85-1.80 (2H, m, H7); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 144.1, 142.8, 138.6, 135.5, 129.6, 127.7, 118.3, 104.6, 62.3, 48.6, 32.8, 28.8, 21.6; **HRMS** (ES⁺) calc. for C₁₅H₂₀O₃NS [M+H]⁺ 294.1158; found 294.1157.


(E)-3-(3-Methyl-1-tosyl-4,5-dihydro-1H-pyrrol-2-yl)acrylaldehyde, 3a




Prepared by General Procedure **H** using **S4** (199 mg, 0.68 mmol). The resulting crude material was purified by flash chromatography (petroleum ether → petroleum ether / EtOAc (1:1)) to give **3a** as a light yellow oil (108 mg, 0.37 mmol, 55%); **IR** (thin film, ν_{max} / cm⁻¹) 3334, 2946, 1738, 1367, 1217, 1021; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 9.59 (1H, d, *J* = 7.8 Hz, H1 (*this peak appears to be an unresolved ddd*)), 7.50 (2H, d, *J* = 8.0 Hz, TsH), 7.37-7.29 (3H, m, TsH and H3), 6.36 (1H, dd, *J* = 16.0 and 7.8 Hz, H2), 3.67 (2H, t, *J* = 8.3 Hz, H6), 2.35 (3H, s, TsCH₃), 1.96 (2H, t, *J* = 8.0 Hz, H7), 1.74 (3H, s, H9); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 193.8, 144.2, 142.0, 138.0, 133.7, 133.2, 131.7, 129.6, 127.8, 49.0, 35.3, 21.6, 14.9; **HRMS** (ES⁺) calc. for C₁₅H₁₈O₃NS [M+H]⁺ 292.1002; found 292.1001.

1.3.2 Cycloaddition reactions of dienal **3a**

3a was reacted with the following dienophiles:





(3'S,5S,7R)-1'-*tert*-Butyl 5-ethyl 2'-oxo-7-(2-oxoethyl)-1-tosyl-1,2,3,4,5,7-hexahydrospiro[indole-6,3'-indoline]-1',5-dicarboxylate, **11a**




Prepared by General Procedure K using catalyst (*S*)-**10** (3.2 μ L, 0.02 mmol, 0.2 equiv.), **3a** (21.8 mg, 0.075 mmol, 1.5 equiv.) and olefinic oxindole **9a** (15.8 mg, 0.050 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave **11a** as a yellow oil (25.5 mg, 0.042 mmol, 84%); $[\alpha]_D^{25} -13.7$ ($c = 1.0$, CHCl₃); IR (thin film, ν_{max} / cm⁻¹) 2925, 1716, 1598, 1348, 1210, 1369, 1346, 706; ¹H NMR (400 MHz, CDCl₃) δ_H 9.69 (1H, s, H9), 7.98 (1H, d, $J = 7.8$ Hz, PhH), 7.36-7.27 (3H, m, TsH and PhH), 7.03 (2H, d, $J = 7.9$ Hz, TsH), 6.76 (1H, td, $J = 7.6$ and 1.0 Hz, PhH), 6.55 (1H, d, $J = 6.8$ Hz, PhH), 4.01-3.82 (3H, m, H2 and OCH₂CH₃), 3.77-3.61 (2H, m, H2 and H7), 3.32 (dd, $J = 11.4$ and 7.0 Hz, H5), 3.23 (dd, $J = 18.9$ and 9.1 Hz, H8), 3.03 (1H, dd, $J = 19.0$ and 1.4 Hz, H8), 2.71 (1H, dd, $J = 18.5$ and 6.9 Hz, H4), 2.49-2.39 (6H, m, H4, H3 and TsCH₃), 1.63 (9H, s, C(CH₃)₃), 0.99 (3H, t, $J = 7.1$ Hz, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ_C 198.2, 176.3, 171.2, 149.0, 143.6, 139.8, 135.8, 133.7, 133.6, 129.7, 128.0, 127.5, 123.7, 122.9, 120.4, 115.2, 83.9, 61.0, 49.9, 49.1, 43.3, 41.4, 36.8, 30.8, 28.0, 25.5, 21.5, 13.6; HRMS (ES⁺) calc. for C₃₂H₃₇O₈N₂S [M+H]⁺ 609.2265; found 609.2265.

HPLC data is listed on the next page.


Chiralpak IB (15% IPA in hexane, flow rate = 1.3 mL/min, 230 nm) Minor diastereomer: t_R major – 9.6 min, minor – 18.2 min; Major diastereomer: t_R major – 12.8 min, minor – 25.7 min. (98% ee).



Proof of stereochemistry for oxindole cycloadditions: Cycloadduct **11a** was used to assign the relative stereochemistry of the cycloaddition through ^1H NMR nOe experiments (1D nOe / 2D NOESY). On the beta face (as depicted below), enhancements were seen between H5 and H8, indicating these groups to be on the same face. On the alpha face, enhancements between H7 and one of the aryl protons of the oxindole, indicating these groups to be on the same face.





(3'S,5S,7R)-1'-*tert*-Butyl 5-ethyl 5'-chloro-2'-oxo-7-(2-oxoethyl)-1-tosyl-1,2,3,4,5,7-hexahydrospiro[indole-6,3'-indoline]-1',5-dicarboxylate, 11b




Prepared by General Procedure **K** using catalyst (*S*)-**10** (3.2 μ L, 0.02 mmol, 0.2 equiv.), **3a** (21.8 mg, 0.075 mmol, 1.5 equiv.) and olefinic oxindole **9b** (17.5 mg, 0.050 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave **11b** as a light yellow oil (22 mg, 0.034 mmol, 68%); $[\alpha]_D^{25}$

-15.6 ($c = 1.2$, CHCl_3); **IR** (thin film, ν_{max} / cm^{-1}) 2982, 1790, 1762, 1727, 1473, 1272, 1151, 909, 728; **$^1\text{H NMR}$** (500 MHz, CDCl_3) δ_{H} 9.69 (1H, s, H9), 7.97 (1H, d, $J = 8.7$ Hz, PhH), 7.34 (2H, d, $J = 8.2$ Hz, TsH), 7.28 (1H, dd, $J = 8.7$ and 2.2, PhH), 7.09 (2H, d, $J = 8.0$ Hz, TsH), 6.44 (1H, d, $J = 2.1$ Hz, PhH), 4.01 (1H, td, $J = 10.8$ and 6.3 Hz, H2), 3.96-3.83 (2H, m, OCH_2CH_3), 3.74-3.59 (2H, m, H2 and H7), 3.32 (1H, dd, $J = 11.6$ and 7.1 Hz, H5), 3.21 (1H, dd, $J = 19.1$ and 9.0 Hz, H4), 3.08 (1H, dd, $J = 19.1$ and 1.2 Hz, H4), 2.73 (1H, dd, $J = 18.5$ and 7.0 Hz, H8), 2.54-2.44 (2H, m, H8 and H3), 2.41 (3H, s, TsCH_3), 2.39-2.35 (1H, m, H3), 1.63 (9H, s, $\text{C(CH}_3)_3$), 1.04 (3H, t, $J = 7.1$ Hz, OCH_2CH_3); **$^{13}\text{C NMR}$** (126 MHz, CDCl_3) δ_{C} 198.0, 175.7, 171.1, 148.9, 144.1, 138.6, 135.7, 133.4, 132.4, 130.0, 128.9, 128.1, 127.2, 123.1, 119.7, 116.4, 84.3, 61.3, 50.0, 49.1, 43.3, 41.3, 36.5, 30.6, 28.0, 25.4, 21.6, 13.7; **HRMS** (ES^+) calc. for $\text{C}_{32}\text{H}_{35}\text{O}_8\text{N}_2\text{ClNaS}$ $[\text{M}+\text{Na}]^+$ 665.1694; found 665.1686.

Chiralpak IA (20% IPA in hexane, flow rate = 1.0 mL/min, 254 nm) t_{R} major – 10.0 min, minor – 8.2 min (>99% ee).






(3'S,5S,7R)-1'-*tert*-Butyl 5-ethyl 5'-methoxy-2'-oxo-7-(2-oxoethyl)-1-tosyl-1,2,3,4,5,7-hexahydrospiro[indole-6,3'-indoline]-1',5-dicarboxylate, 11c




Prepared by General Procedure K using catalyst (*S*)-10 (3.2 μ L, 0.02 mmol, 0.2 equiv.), 3a (21.8 mg, 0.075 mmol, 1.5 equiv.) and olefinic oxindole 9c (17.3 mg, 0.05 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave 11c as a red oil (29 mg, 0.045 mmol, 91%); $[\alpha]_D^{25} = -2.03$ ($c = 1.3$, CHCl₃); IR (thin film, ν_{max} / cm⁻¹) 2931, 1787, 1757, 1722, 1597, 1485, 1279, 1155, 771; ¹H NMR (400 MHz, CDCl₃) δ H 9.63 (1H, s, H9), 7.86 (1H, d, $J = 8.9$ Hz, PhH), 7.26 (2H, d, $J = 8.2$ Hz, TsH), 6.98 (2H, d, $J = 8.1$ Hz, TsH), 6.82-6.72 (1H, m, PhH), 6.08 (1H, d, $J = 2.6$ Hz, PhH), 3.99-3.73 (3H, m, H2 and OCH₂CH₃), 3.66-3.51 (2H, m, H2 and H7), 3.49 (3H, s, OCH₃), 3.28-3.13 (2H, m, H5 and H8), 2.97 (1H, d, $J = 17.9$ Hz, H8), 2.64 (1H, dd, $J = 18.4$ and 6.6 Hz, H4), 2.40-2.33 (6H, m, H4, H3 and TsCH₃), 1.57 (9H, s, C(CH₃)₃), 0.95 (3H, t, $J = 7.1$ Hz, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ C 198.0, 176.2, 171.2, 155.7, 149.1, 143.6, 135.9, 133.5, 133.3, 131.7, 129.8, 127.5, 120.1, 115.9, 112.0, 110.0, 83.8, 61.1, 54.8, 50.2, 49.0, 43.4, 41.3, 36.8, 30.7, 28.0, 25.5, 21.5, 13.6; HRMS (ES⁺) calc. for C₃₃H₃₉O₉N₂S [M+H]⁺ 639.2370; found 639.2365.

Chiralpak IB (20% IPA in hexane, flow rate = 1.3 mL/min, 230 nm) t_R major – 9.8 min, minor – 25.9 min and t_R major – 14.4 min, minor – 25.9 min (>99% ee).




(3'S,5S,7R)-di-*tert*-Butyl 2'-oxo-7-(2-oxoethyl)-1-tosyl-1,2,3,4,5,7-hexahydrospiro[indole-6,3'-indoline]-1',5-dicarboxylate, 11d




Prepared by General Procedure K using catalyst (*S*)-10 (3.2 μ L, 0.02 mmol, 0.2 equiv.), 3a (21.8 mg, 0.075 mmol, 1.5 equiv.) and olefinic oxindole 9d (17.2 mg, 0.05 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave 11d as a light yellow oil (22 mg, 0.034 mmol, 69%, *dr* 3.6:1); $[\alpha]_D^{25} -16.9$ ($c = 1$, CHCl₃); IR (thin film, ν_{max} / cm⁻¹) 2926, 1791, 1760, 1722, 1604, 1479, 1348, 1152, 1090, 815; ¹H NMR (400 MHz, CDCl₃) δ _H 9.69 (1H, s, H9), 7.96 (1H, t, *J* = 8.4 Hz, PhH), 7.36-7.25 (3H, m, TsH and PhH), 7.02 (2H, d, *J* = 8.0 Hz, TsH), 6.77 (1H, t, *J* = 7.5 Hz, PhH), 6.56 (1H, d, *J* = 7.5 Hz, PhH), 4.00-3.87 (1H, m, H2), 3.69-3.62 (2H, m, H2 and H7), 3.27-3.19 (2H, m, H5 and H8), 2.99 (1H, d, *J* = 17.9 Hz, H8), 2.69-2.56 (1H, m, H4), 2.50-2.34 (6H, m, H4, H3 and TsCH₃), 1.63 (9H, s, C(CH₃)₃), 1.09 (9H, s, C(CH₃)₃); ¹³C NMR (101 MHz, CDCl₃) δ _C 198.2, 176.0, 170.3, 149.2, 143.5, 139.6, 135.4, 133.8, 129.7, 129.7, 128.0, 127.5, 123.7, 123.0, 115.0, 83.9, 82.0, 54.5, 50.2, 49.1, 43.5, 41.6, 36.9, 30.9, 28.0, 27.3, 25.5, 21.5; HRMS (ES⁺) calc. for C₃₄H₄₀O₈N₂NaS [M+Na]⁺ 659.2397; found 659.2391.

Chiralpak IB (20 % IPA in hexane, flow rate = 1.3 mL/min, 254 nm) Minor diastereomer: *t*_Rmajor – 7.3 min, minor – 11.2 min; Major diastereomer: *t*_Rmajor – 9.4 min, minor – 16.2 min (>99% ee).




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.446	MM T	0.3082	456.98883	27.20280	11.4210
2	9.551	MM T	0.3386	1376.97815	67.77059	34.4132
3	11.228	MM T	0.4769	440.77182	14.36648	11.0157
4	16.154	MM T	0.5884	1726.56702	47.98352	43.1501





Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.323	MM T	0.2619	449.79077	29.00819	23.5518
2	9.363	MM T	0.3212	1460.00476	75.75909	76.4482

(E)-Ethyl 4-((5S,6S,7R)-6-nitro-5-phenyl-1-tosyl-2,3,4,5,6,7-hexahydro-1H-indol-7-yl)but-2-enoate, 14a




Prepared by General Procedure J using catalyst (*S*)-**10** (6.5 μ L, 0.020 mmol, 0.2 equiv.), **3a** (40 mg, 0.14 mmol, 1.4 equiv.) and trans- β -nitrostyrene **13a** (14.9 mg, 0.10 mmol, 1.0 equiv.). Purification via column chromatography (petroleum ether / EtOAc (2:1)) to give **14a** as colourless oil (36 mg, 0.071 mmol, 71%); $[\alpha]_D^{25}$ c=127.5 ($c = 1.0$, CHCl₃); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 2925, 1716, 1598, 1548, 1345, 1089; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 7.78 (2H, d, $J = 8.3$ Hz, TsH), 7.39 (2H, d, $J = 8.0$ Hz, TsH), 7.34 - 7.25 (3H, m, PhH), 7.18 (2H, d, $J = 6.7$ Hz, PhH), 6.76 (1H, ddd, $J = 15.5, 9.3$ and 6.1 Hz, H9), 6.02 (1H, d, $J = 15.7$ Hz, H10), 4.71 (1H, dd, $J = 11.4$ and 9.4 Hz, H6), 4.21 (2H, q, $J = 7.1$ Hz, OCH₂CH₃), 3.89 (1H, ddd, $J = 12.9, 8.3$ and 1.3 Hz, H2), 3.74-3.65 (2H, m, H2 and H7), 3.39-3.36 (2H, m, H5 and H8), 2.48 (3H, s, OCH₃), 2.46-2.32 (2H, m, H8 and H4), 2.09 (1H, dd, $J = 18.3$ and 5.3 Hz, H4), 1.84 (1H, dd, $J = 15.9$ and 9.5 Hz, H3), 1.68-1.57 (1H, m, H3), 1.24 (3H, t, $J = 7.1$ Hz, OCH₂CH₃); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 166.3, 144.7, 142.7, 138.3, 134.5, 133.4, 131.4, 129.9, 129.1, 128.3, 127.9, 127.5, 126.0, 91.4, 60.5, 50.8, 45.3, 40.9, 31.6 (2C), 31.3, 21.8, 14.4; **HRMS** (ES⁺) calc. for C₂₇H₃₁O₆N₂S [M+H]⁺ 511.1897, found 511.1898.

Chiralpak IB (20% IPA in hexane, flow rate = 1.2 mL/min, 230 nm) t_{R} major – 7.4 min, minor – 13.4 min (>99% ee).




(E)-Ethyl 4-((5*S*,6*S*,7*R*)-5-(4-chlorophenyl)-6-nitro-1-tosyl-2,3,4,5,6,7-hexahydro-1*H*-indol-7-yl)but-2-enoate, 14b




Prepared by General Procedure **J** using catalyst (*S*)-**10** (6.5 μ L, 0.020 mmol, 0.2 equiv.) and **3a** (40 mg, 0.14 mmol, 1.4 equiv.) and (*E*)-1-chloro-4-(2-nitrovinyl)benzene **13b** (14.9 mg, 0.10 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave the cycloadduct **14b** as light yellow oil (38 mg, 0.070 mmol, 70%). Note: a small amount of the *Z*-alkene (*E*:*Z* = 20:1) was observed (J = 11.6 Hz), but no diastereomer from the cycloaddition could be detected. $[\alpha]_D^{25} -53.8$ (c = 1.2, CHCl₃); **IR** (thin film, ν_{max} / cm⁻¹) 2981, 1714, 1655, 1547, 1319, 1161; **¹H NMR** (400 MHz, CDCl₃) δ _H 7.76 (2H, d, J = 8.3 Hz, TsH), 7.38 (2H, d, J = 8.0 Hz, TsH), 7.29 (2H, d, J = 8.5 Hz, ArH), 7.12 (2H, d, J = 8.5 Hz, ArH), 6.80 (1H, ddd, J = 15.5, 9.4 and 6.0 Hz, H9), 6.02 (1H, d, J = 15.6 Hz, H10), 4.65 (1H, dd, J = 11.5 and 9.5 Hz, H6), 4.20 (2H, q, J = 7.1 Hz, OCH₂CH₃), 3.95 (1H, ddd, J = 12.9, 8.3 and 1.3 Hz, H2), 3.76-3.63 (2H, m, H2 and H7), 3.39-3.26 (2H, m, H5 and H8), 2.48 (3H, s, TsCH₃), 2.44-2.26 (2H, m, H8 and H4), 2.14 (1H, dd, J = 18.0, 4.9 Hz, H4), 1.91 (1H, dd, J = 15.7, 9.1 Hz, H3), 1.68-1.64 (1H, m, H3), 1.31 (3H, t, J = 7.1 Hz, OCH₂CH₃). **¹³C NMR** (101 MHz, CDCl₃) δ _C 166.2, 144.6, 142.4, 136.7, 134.5, 134.1, 133.3, 131.0, 129.8, 129.2, 128.8, 127.8, 126.0, 91.2, 60.5, 50.6, 44.6, 40.8, 31.4, 31.4, 31.2, 21.7, 14.2; **HRMS** (ES⁺) calc. for C₂₇H₃₀O₆N₂CIS [M+H]⁺ 545.1507; found 545.1507.


Chiralpak IB (15% IPA in hexane, flow rate = 1.3 mL/min, 230 nm) t_{R} major – 7.8 min, minor – 8.7 min (>99% ee).




(E)-Ethyl 4-((5*S*,6*S*,7*R*)-5-(4-bromophenyl)-6-nitro-1-tosyl-2,3,4,5,6,7-hexahydro-1*H*-indol-7-yl)but-2-enoate, 14c




Prepared by General Procedure J using catalyst (*S*)-**10** (6.5 μ L, 0.02 mmol, 0.2 equiv.), **3a** (40 mg, 0.14 mmol, 1.4 eq.) and (*E*)-1-bromo-4-(2-nitrovinyl)benzene **13c** (22.6 mg, 0.10 mmol, 1.0 eq.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave **14c** as a red oil (49 mg, 0.083 mmol, 83%); Note: a small amount of the *Z*-alkene (*E*:*Z* ~ 20:1) was observed ($J = 11.6$ Hz), in addition to the 13.5:1 ratio of diastereomers from the cycloaddition. $[\alpha]_D^{25} -56.5$ ($c = 1.5$, CHCl₃); **IR** (thin film, ν_{max} / cm⁻¹) 2924, 1714, 1551, 1316, 1160, 982; **¹H NMR** (400 MHz, CDCl₃) δ _H 7.76 (2H, d, $J = 8.2$ Hz, TsH), 7.43 (2H, d, $J = 8.3$ Hz, TsH), 7.38 (2H, d, $J = 8.1$ Hz, ArH), 7.06 (2H, d, $J = 8.4$ Hz, ArH), 6.80 (1H, ddd, $J = 15.5$, 9.4 and 6.0 Hz, H9), 6.02 (1H, d, $J = 15.6$ Hz, H10), 4.65 (1H, dd, $J = 11.5$ and 9.5 Hz, H6), 4.20 (2H, q, $J = 7.1$ Hz, OCH₂CH₃), 3.95 (1H, dd, $J = 13.1$ and 7.2 Hz, H2), 3.72-3.64 (2H, m, H2 and H7), 3.32 (2H, td, $J = 11.2$ and 5.3 Hz, H5 and H8), 2.47 (3H, s, TsCH₃), 2.45-2.26 (2H, m, H8 and H4), 2.14 (1H, dd, $J = 18.2$ and 5.1 Hz, H4), 1.90 (1H, dd, $J = 16.0$ and 9.3 Hz, H3), 1.67-1.58 (1H, m, H3), 1.31 (3H, t, $J = 7.1$ Hz, OCH₂CH₃); **¹³C NMR** (101 MHz, CDCl₃) δ _C 166.1, 144.6, 142.3, 137.2, 134.5, 133.3, 132.1, 131.0, 129.8, 129.1, 127.7, 126.0, 122.1, 91.0, 60.4, 50.6, 44.6, 40.7, 31.4, 31.4, 31.1, 21.7, 14.2; **HRMS** (ES⁺) calc. for C₂₇H₃₀O₆N₂BrS [M+H]⁺ 589.1002; found 589.0996, 591.0974. Chiralpak IB (7% IPA in hexane, flow rate = 1.3 mL/min, 230 nm) *t*_Rmajor – 14.3 min, minor – 16.9 min (>99% ee).




(E)-Ethyl 4-((5*S*,6*S*,7*R*)-6-nitro-1-tosyl-5-(4-(trifluoromethyl)phenyl)-2,3,4,5,6,7-hexahydro-1*H*-indol-7-yl)but-2-enoate, 14d




Prepared by General Procedure J using catalyst (*S*)-**10** (6.5 μ L, 0.02 mmol, 0.20 equiv.), **3a** (40 mg, 0.14 mmol, 1.4 equiv.) and (*E*)-1-(2-nitrovinyl)-4-(trifluoromethyl)benzene **13d** (21.7 mg, 0.10 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave **14d** as a colourless oil (39.5 mg, 0.068 mmol, 68%); Note: a small amount of the *Z*-alkene (*E*:*Z* ~ 20:1) was observed ($J = 11.6$ Hz), in addition to the 8:1 ratio of diastereomers from the cycloaddition. $[\alpha]_D^{25} -40.0$ ($c = 1.0$, CHCl_3); **IR** (thin film, ν_{max} / cm^{-1}) 2926, 1716, 1551, 1651, 1348, 1324, 1160; **1H NMR** (400 MHz, CDCl_3) δ_{H} 7.77 (2H, d, $J = 8.3$ Hz, TsH), 7.57 (2H, d, $J = 8.1$ Hz, TsH), 7.32 (2H, d, $J = 8.1$ Hz, ArH), 7.25 (2H, d, $J = 8.1$ Hz, ArH), 6.81 (1H, ddd, $J = 15.5$, 9.4 and 6.0 Hz, H9), 6.03 (1H, d, $J = 15.9$ Hz, H10), 4.72 (1H, dd, $J = 11.6$ and 9.5 Hz, H6), 4.21 (2H, q, $J = 7.1$ Hz, OCH_2CH_3), 3.96 (1H, dd, $J = 12.4$ and 7.8 Hz, H2), 3.74-3.65 (2H, m, H2 and H7), 3.43 (1H, td, $J = 11.3$ and 5.4 Hz, H5), 3.37-3.30 (1H, m, H8), 2.48 (3H, s, OCH_3), 2.54-2.27 (2H, m, H8 and H4), 2.17 (1H, dd, $J = 18.2$ and 5.1 Hz, H4), 1.92 (1H, dd, $J = 15.9$ and 9.2 Hz, H3), 1.69-1.63 (1H, m, H3), 1.31 (3H, t, $J = 7.1$ Hz, OCH_2CH_3); **13C NMR** (101 MHz, CDCl_3) δ_{C} 166.1, 144.6, 142.2, 133.2, 130.8, 130.2 (q, $J = 23.7$ Hz), 130.0, 129.8, 127.8, 127.7, 126.1, 126.0, 126.0, 125.9, 125.9, 90.8, 60.4, 50.6, 44.9, 40.8, 31.4, 31.1, 21.7, 14.2; **HRMS** (ES^+) calc. for $\text{C}_{28}\text{H}_{30}\text{O}_6\text{N}_2\text{F}_3\text{S}$ [$\text{M}+\text{H}]^+$ 579.1771; found 579.1770. Chiralpak IA (7% IPA in hexane, flow rate = 1.3 mL/min, 254 nm) t_{R} major – 12.6 min, minor – 15.6 min (>99% ee).




(E)-Ethyl 4-((5*S*,6*S*,7*R*)-5-(4-methoxyphenyl)-6-nitro-1-tosyl-2,3,4,5,6,7-hexahydro-1*H*-indol-7-yl)but-2-enoate, 14e



Prepared by General Procedure J using catalyst (*S*)-**10** (6.5 μ L, 0.02 mmol, 0.20 equiv.), **3a** (40 mg, 0.14 mmol, 1.4 equiv.) and (*E*)-1-methoxy-4-(2-nitrovinyl)benzene **13e** (17.9 mg, 0.10 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave **14e** as a red oil (44 mg, 0.081 mmol, 81%); Note: a small amount of the *Z*-alkene (*E*:*Z* ~ 30:1) was observed ($J = 11.6$ Hz), but no diastereomer from the cycloaddition could be detected. $[\alpha]_D^{25} -48.1$ ($c = 1.2$, CHCl₃); **IR** (thin film, ν_{max} / cm⁻¹) 2924, 1715, 1548, 1516, 1346, 1249, 1270, 1180, 1158; **¹H NMR** (500 MHz, CDCl₃) δ _H 7.76 (2H, d, $J = 8.3$ Hz, TsH), 7.38 (2H, d, $J = 8.0$ Hz, TsH), 7.10 (2H, d, $J = 8.7$ Hz, ArH), 6.86 (2H, d, $J = 8.8$ Hz, ArH), 6.82 (1H, dd, $J = 9.4$ and 6.0 Hz, H9), 6.00 (1H, d, $J = 15.7$ Hz, H10), 4.64 (1H, dd, $J = 11.4$, 9.4 Hz, H6), 4.20 (2H, q, $J = 7.1$ Hz, OCH₂CH₃), 3.94 (1H, ddd, $J = 12.9$, 8.3 and 1.2 Hz, H2), 3.76 (3H, s, OCH₃), 3.73-3.64 (2H, m, H2' and H7), 3.32-3.25 (2H, m, H5 and H8), 2.47 (3H, s, TsCH₃), 2.43-2.29 (2H, m, H8 and H4), 2.12 (1H, dd, $J = 18.3$ and 5.2 Hz, H4), 1.89 (1H, dd, $J = 16.0$ and 9.4 Hz, H3), 1.65-1.56 (1H, m, H3'), 1.30 (3H, t, $J = 7.1$ Hz, OCH₂CH₃); **¹³C NMR** (126 MHz, CDCl₃) δ _C 166.2, 159.2, 144.5, 142.6, 134.3, 133.2, 131.4, 130.0, 129.7, 128.4, 127.7, 125.8, 114.2, 91.6, 60.4, 55.2, 50.6, 44.4, 40.7, 31.4, 31.4, 31.1, 21.6, 14.2; **HRMS** (ES⁺) calc. for C₂₈H₃₃O₇N₂S [M+H]⁺ 541.2003; found 541.1998. Chiralpak IB (15% IPA in hexane, flow rate = 1.3 mL/min, 254 nm) t_R major – 10.0 min, minor – 11.1 min (>99% ee).





(E)-Ethyl 4-((5*R*,6*R*,7*R*)-5-(furan-2-yl)-6-nitro-1-tosyl-2,3,4,5,6,7-hexahydro-1*H*-indol-7-yl)but-2-enoate, 14f




Prepared by General Procedure J using catalyst (*S*)-**10** (6.5 μ L, 0.02 mmol, 0.20 equiv.), **3a** (40 mg, 0.14 mmol, 1.4 equiv.) and (*E*)-2-(2-nitrovinyl)furan **13f** (13.9 mg, 0.10 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave the corresponding cycloadduct **14f** as a black oil (36 mg, 0.072 mmol, 72%); Note: a small amount of the *Z*-alkene (*E*:*Z* ~ 20:1) was observed ($J = 11.6$ Hz), in addition to the 9:1 ratio of diastereomers from the cycloaddition. $[\alpha]_D^{25} -30.0$ ($c = 1.25$, CHCl_3); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 2926, 1717, 1554, 1357, 1160, 1158, 729; **¹H NMR** (400 MHz, CDCl_3) δ_{H} 7.74 (2H, d, $J = 8.3$ Hz, TsH), 7.39 (2H, d, $J = 8.3$ Hz, TsH), 7.37 (1H, dd, $J = 1.8$ and 0.8 Hz, FurH), 6.79 (1H, ddd, $J = 15.5$, 8.9 and 6.4 Hz, H9), 6.28 (1H, dd, $J = 3.2$ and 1.9 Hz, FurH), 6.13 (1H, d, $J = 3.3$ Hz, FurH), 5.97 (1H, d, $J = 15.6$ Hz, H10), 4.69 (1H, dd, $J = 10.6$ and 8.8 Hz, H6), 4.19 (2H, q, $J = 7.1$ Hz, OCH_2CH_3), 3.92 (1H, ddd, $J = 12.9$, 8.5 and 1.7 Hz, H2), 3.78-3.72 (1H, m, H7), 3.68 (1H, ddd, $J = 12.9$, 11.8 and 9.6 Hz, H2), 3.56 (1H, td, $J = 10.4$ and 5.5 Hz, H5), 3.09-3.02 (1H, m, H8), 2.54-2.42 (2H, m, H8 and H4), 2.46 (3H, s, OCH_3), 2.19 (1H, dd, $J = 18.1$ and 5.0 Hz, H4), 1.94 (1H, dd, $J = 16.0$ and 9.4 Hz, H3), 1.70-1.61 (1H, m, H3), 1.29 (3H, t, $J = 7.1$ Hz, OCH_2CH_3); **¹³C NMR** (101 MHz, CDCl_3) δ_{C} 166.1, 151.2, 144.5, 142.6, 142.5, 134.1, 133.2, 129.8, 129.8, 127.7, 125.8, 110.4, 107.5, 89.3, 60.4, 50.4, 39.9, 37.9, 31.5, 31.1, 27.8, 21.6, 14.2; **HRMS** (ES⁺) calc. for $\text{C}_{25}\text{H}_{29}\text{O}_7\text{N}_2\text{S} [\text{M}+\text{H}]^+$ 501.1690; found 501.1685.


Chiralpak IB (5% IPA in hexane, flow rate = 1.3 mL/min, 254 nm) t_{R} major – 17.0 min, minor – 24.3 min (91% ee).



Proof of stereochemistry for nitroalkene cycloadditions: Cycloadduct **14f** was used to assign the relative stereochemistry of the cycloaddition through ¹H NMR nOe experiments (1D nOe / 2D NOESY). On the beta face (as depicted below), enhancements were seen between H6 and H9, and H6 and one of H4, indicating these groups to be on the same face. On the alpha face, enhancements between H5 and H7, and between H5 and the second of the H4 atoms, are indicative of these groups to be on the same face.




(E)-Ethyl 4-((4'R,5S,7R)-5'-oxo-2',5-diphenyl-1-tosyl-1,2,3,4,5,7-hexahydro-5'H-spiro[indole-6,4'-oxazol]-7-yl)but-2-enoate, 16a




Prepared by General Procedure J using catalyst (*S*)-**10** (6.5 μ L, 0.02 mmol, 0.2 equiv.), **3a** (40 mg, 0.14 mmol, 1.4 equiv.) and olefinic azlactone **15a** (24.9 mg, 0.1 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave the corresponding cycloadduct **16a** as a yellow oil (30.6 mg, 0.050 mmol, 50%); $[\alpha]_D^{25} -161.3$ ($c = 0.6$, CHCl₃); IR (thin film, ν_{max} / cm⁻¹) 2924, 1810, 1712, 1652, 1552, 1347, 1159; ¹H NMR (400 MHz, CDCl₃) δ H 7.96 (2H, d, $J = 7.2$ Hz, PhH), 7.83 (2H, d, $J = 8.1$ Hz, TsH), 7.62 (1H, t, $J = 7.4$ Hz, PhH), 7.52 (2H, t, $J = 7.6$ Hz, PhH), 7.33 (2H, d, $J = 8.1$ Hz, TsH), 7.23-7.12 (6H, m, H9 and PhH), 6.11 (1H, d, $J = 15.6$ Hz, H10), 4.21 (2H, q, $J = 7.1$ Hz, OCH₂CH₃), 3.80 (2H, dd, $J = 9.8$ and 6.7 Hz, H2), 3.55 (1H, br s, H7), 3.46 (1H, dd, $J = 11.7$ and 5.6 Hz, H5), 3.17-3.11 (1H, m, H8), 2.92-2.86 (1H, m, H8), 2.65 (1H, dd, $J = 16.6$ and 12.1 Hz, H4), 2.50 (3H, s, TsCH₃), 2.33 (1H, dd, $J = 17.3$ and 5.5 Hz, H4), 2.10-1.92 (2H, m, H3), 1.31 (3H, t, $J = 7.1$ Hz, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ C 176.5, 166.5, 161.0, 145.7, 143.7, 137.5, 134.4, 133.9, 132.9, 129.5, 129.02, 128.8, 128.3, 128.1, 127.9, 127.8, 126.9, 125.8, 123.8, 75.3, 60.2, 49.8, 43.1, 42.5, 31.6, 30.8, 29.5, 21.7, 14.3; HRMS (ES⁺) calc. for C₃₅H₃₅O₆N₂S [M+H]⁺ 611.2210; found 611.2205.

Chiralpak IB (7% IPA in hexane, flow rate = 1.3 mL/min, 230 nm) $t_{R\text{major}}$ – 13.4 min, minor – 11.8 min (>99% ee).




(E)-Ethyl 4-((4'R,5S,7R)-5-(4-bromophenyl)-5'-oxo-2'-phenyl-1-tosyl-1,2,3,4,5,7-hexahydro-5'H-spiro[indole-6,4'-oxazol]-7-yl)but-2-enoate, 16b




Prepared by General Procedure J using catalyst (*S*)-**10** (6 μ L, 0.02 mmol, 0.2 equiv.), **3a** (40 mg, 0.14 mmol, 1.4 equiv.) and olefinic azlactone **15b** (32.6 mg, 0.1 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave the corresponding cycloadduct **16b** as a yellow oil (27 mg, 0.039 mmol, 39%); $[\alpha]_D^{25} -106.2$ ($c = 1.2$, CHCl₃); IR (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 2925, 1810, 1712, 1651, 1494, 1346, 1158; ¹H NMR (400 MHz, CDCl₃) δ 7.90 (2H, d, $J = 7.2$ Hz, PhH), 7.81 (2H, d, $J = 8.2$ Hz, TsH), 7.63 (1H, t, $J = 7.4$ Hz, PhH), 7.54 (2H, t, $J = 7.6$ Hz, PhH), 7.32 (1H, d, $J = 8.4$ Hz, TsH), 7.00 (2H, d, $J = 8.4$ Hz, *p*-BrC₆H₄), 7.16 (1H, ddd, $J = 15.5$, 8.5 and 7.0 Hz, H9), 6.93 (2H, d, $J = 8.5$ Hz, *p*-BrC₆H₄), 6.10 (2H, d, $J = 15.6$ Hz, H10), 4.21 (2H, q, $J = 7.1$ Hz, OCH₂CH₃), 3.80 (2H, dd, $J = 9.9$ and 6.7 Hz, H2), 3.47 (1H, br s, H7), 3.42 (1H, dd, $J = 11.7$ and 5.6 Hz, H5), 3.09-3.02 (1H, m, H8), 2.87 (1H, ddd, $J = 15.0$, 8.5 and 4.1 Hz, H8), 2.55-2.48 (1H, m, H4), 2.43 (3H, s, TsH), 2.30 (1H, dd, $J = 17.3$ and 5.6 Hz, H4), 2.02-1.87 (2H, m, H3), 1.31 (3H, t, $J = 7.1$ Hz, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 176.4, 166.5, 161.2, 145.5, 143.8, 136.7, 134.4, 133.9, 133.1, 131.5, 130.7, 129.6, 128.9, 128.1, 127.9, 126.5, 125.6, 124.0, 122.0, 75.1, 60.3, 49.9, 42.6, 42.5, 31.6, 30.8, 29.5, 21.8, 14.3; HRMS (ES⁺) calc. for C₃₅H₃₃BrN₂O₆S [M]⁺ 688.1243; found 689.8211, 690.8067.

Chiralpak IA (10% IPA in hexane, flow rate = 1.0 mL/min, 230 nm) $t_{R\text{major}} - 17.13$ min, minor – 11.6 min (>99% ee).




(E)-Ethyl 4-((4'R,5S,7R)-5-(4-methoxyphenyl)-5'-oxo-2'-phenyl-1-tosyl-1,2,3,4,5,7-hexahydro-5'H-spiro[indole-6,4'-oxazol]-7-yl)but-2-enoate, 16c




Prepared by General Procedure J using catalyst (*S*)-10 (6.5 μ L, 0.02 mmol, 0.2 equiv.), 3a (40 mg, 0.14 mmol, 1.4 equiv.) and olefinic azlactone 15c (27.9 mg, 0.1 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave the corresponding cycloadduct 16c as a brown oil (23 mg, 0.036 mmol, 36%, *dr* 17:1); $[\alpha]_D^{25} -107.1$ ($c = 0.75$, CHCl₃); IR (thin film, ν_{max} / cm⁻¹) 2924, 1801, 1719, 1652, 1349, 1160, 1039; ¹H NMR (500 MHz, CDCl₃) δ _H 7.96 (2H, d, $J = 8.5$ Hz, PhH), 7.83 (2H, d, $J = 8.2$ Hz, TsH), 7.61 (1H, t, $J = 6.9$ Hz, PhH), 7.52 (2H, t, $J = 7.7$ Hz, PhH), 7.32 (2H, d, $J = 8.1$ Hz, TsH), 7.20–7.15 (1H, m, H9), 7.04 (2H, d, $J = 8.7$ Hz, ArH), 6.66 (2H, d, $J = 8.7$ Hz, ArH), 6.10 (1H, d, $J = 15.6$ Hz, H10), 4.21 (2H, q, $J = 7.1$ Hz, OCH₂CH₃), 3.79 (2H, dd, $J = 10.0$ and 6.6 Hz, H2), 3.70 (3H, s, OCH₃), 3.54 (1H, brs, H7), 3.42 (1H, dd, $J = 11.7$ and 5.6 Hz, H5), 3.16 - 3.10 (1H, m, H8), 2.91 - 2.88 (1H, m, H8), 2.60 (1H, dd, $J = 16.7$ and 12.0 Hz, H4), 2.50 (3H, s, TsH), 2.29 (1H, dd, $J = 17.3$ and 5.6 Hz, H4), 2.07 - 1.93 (2H, m, H3), 1.31 (3H, t, $J = 7.1$ Hz, OCH₂CH₃); ¹³C NMR (126 MHz, CDCl₃) δ _C 176.6, 166.5, 160.9, 159.0, 145.8, 143.7, 134.4, 133.8, 132.8, 130.0, 129.49, 129.4, 128.8, 128.1, 127.8, 127.0, 125.8, 123.8, 113.6, 75.5, 60.2, 55.1, 49.8, 42.4, 42.3, 31.6, 30.8, 29.7, 21.7, 14.3. HRMS (ES⁺) calc. for C₃₆H₃₆O₇N₂NaS [M+Na]⁺ 663.2135; found 663.2133.

Chiralpak IA (10% IPA in hexane, flow rate = 1.0 mL/min, 230 nm) $t_{R\text{major}} - 22.4$ min, minor – 14.4 min (>99% ee).




Proof of stereochemistry for azlactone cycloadditions: Cycloadduct **16c** was used to assign the relative stereochemistry of the cycloaddition through ^1H NMR nOe experiments (1D nOe / 2D NOESY). On the alpha face (as depicted below), a strong enhancement was seen between H5 and H9, indicating these groups to be on the same face.




1.3.3 Synthesis of dienals **4a-d** and **8a**

Dienals **4a-d** and **8a** were synthesized according to the following scheme:




(E)-Methyl (6-((tert-butyldimethylsilyl)oxy)hex-3-en-1-yl)(tosyl)carbamate, **S6**




Prepared by General Procedure A using **S5** (1.20 g, 5.21 mmol). The resulting crude material was purified by flash chromatography (petroleum ether / Et_2O (9:1)) to give **S6** as a colourless oil (1.85 g, 4.19 mmol, 80%); **IR** (thin film, ν_{max} / cm^{-1}) 2955, 2857, 1736, 1444, 1359, 1281, 1168, 1089, 835; **¹H NMR** (400 MHz, CDCl_3) δ_{H} 7.83 (2H, d, J = 8.0 Hz, TsH), 7.30 (2H, d, J = 8.0 Hz, TsH), 5.47 (2H, m, H3 and H4), 3.86–3.82 (2H, m, H6), 3.68 (3H, s, CO_2Me), 3.60 (2H, t, J = 6.9 Hz, H1), 2.43 (3H, s, TsCH_3), 2.46–2.35 (2H, m, H5), 2.21 (2H, q, J = 6.6 Hz, H2), 0.89 (9H, s, $\text{SiC(CH}_3)_3$), 0.05 (6H, s, $\text{Si(CH}_3)_2$); **¹³C NMR** (101 MHz, CDCl_3) δ_{C} 152.8, 144.5, 136.6, 130.0, 129.3, 128.3, 127.4, 63.0, 53.7, 47.0, 36.2, 33.3, 25.9, 21.6, 18.3, –5.3; **HRMS** (ES^+) calc. for $\text{C}_{21}\text{H}_{36}\text{O}_5\text{NSSi}$ [$\text{M}+\text{H}]^+$ 442.2078; found 442.2074.

(E)-N-(6-((tert-butyldimethylsilyl)oxy)hex-3-en-1-yl)-4-methylbenzenesulfonamide, S7




Prepared by General Procedure **B** using carbamate **S6** (1.80 g, 4.08 mmol). The resulting crude material was purified by flash chromatography (petroleum ether / Et₂O (4:1)) to give **S7** as a colourless oil (1.49 g, 3.88 mmol, 95%); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 3284, 2954, 2929, 2857, 1599, 1325, 1219, 1159, 1094, 908; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 7.73 (2H, d, *J* = 8.3 Hz, TsH), 7.28 (2H, t, *J* = 8.7 Hz, TsH), 5.45-5.38 (1H, m, H4), 5.29-5.22 (1H, m, H3), 4.62 (1H, br s, NH), 3.57 (2H, t, *J* = 6.7 Hz, H6), 2.96 (2H, q, *J* = 6.6 Hz, H1), 2.42 (3H, s, TsCH₃), 2.23-2.06 (4H, m, H2 and H5), 0.87 (9H, s, SiC(CH₃)₃), 0.02 (6H, s, Si(CH₃)₂); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 143.3, 136.9, 130.7, 129.6, 127.5, 127.1, 62.8, 42.5, 36.1, 32.5, 25.9, 21.5, 18.3, -5.3; **HRMS** (ES⁺) calc. for C₁₉H₃₄O₃NSSi [M+H]⁺ 384.2023; found 384.2021.

(E)-N-(6-((tert-Butyldimethylsilyl)oxy)hex-3-en-1-yl)-4-methyl-N-(oct-1-yn-1-yl)benzenesulfonamide, 5b




Prepared by General Procedure **C** using sulfonamide **S7** (1.50 g, 3.91 mmol, 1.0 equiv.) and 1-bromoocooct-1-yn (940 mg, 4.80 mmol, 1.2 equiv.). The resulting crude material was purified by flash chromatography (petroleum ether / EtOAc (95:5)) to give **5b** as a colourless oil (1.45 g, 2.95 mmol, 75%); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 2929, 2857, 1739, 1463, 1366, 1254, 1170, 1093, 968, 836, 776; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 7.73 (2H, d, *J* = 8.3 Hz, TsH), 7.28 (2H, d, *J* = 8.1 Hz, TsH), 5.51-5.37 (1H, m, H3), 5.34-5.26 (1H, m, H4), 3.54 (2H, t, *J* = 6.8 Hz, H1), 3.25-3.21 (2H, m, H6), 2.40 (3H, s, TsCH₃), 2.30 (2H, dt, *J* = 7.5 and 7.0 Hz, H2), 2.25 (2H, t, *J* = 7.0 Hz, H9), 2.17 (2H, dt, *J* = 6.5 and 6.5 Hz, H5), 1.46-1.39 (2H, m, H10), 1.33-1.14 (6H, m, H11-H13), 0.86-0.83 (3H, m, H14), 0.84 (9H, s, SiC(CH₃)₃), 0.00 (6H, s, Si(CH₃)₂); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 144.2, 134.7, 129.9, 129.6, 127.6, 127.2, 72.9, 70.5, 63.0, 51.2, 36.3, 31.3, 31.2, 28.9, 28.5, 25.9, 22.6, 21.6, 18.5, 18.4, 14.1, -5.2; **HRMS** (ES⁺) calc. for C₂₇H₄₆O₃NSSi [M+H]⁺ 492.2962; found 492.2958.

(Z)-3-((E)-3-((tert-butyldimethylsilyl)oxy)prop-1-en-1-yl)-2-heptylidene-1-tosylpyrrolidine, S8a




Prepared by General Procedure F using ynamide **5b** (1.29 g, 2.62 mmol). The crude material was purified by flash chromatography (petroleum ether / EtOAc (95:5)) to give **S8a** as a colourless oil (1.20 g, 2.44 mmol, 93%); **IR** (thin film, ν_{max} / cm⁻¹) 2955, 2928, 1355, 1253, 1164, 1091, 835; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 7.63 (2H, d, *J* = 8.2 Hz, TsH), 7.23 (2H, d, *J* = 8.0 Hz, TsH), 5.34 (1H, dt, *J* = 15.3 and 4.8 Hz, H2), 5.24-5.16 (1H, m, H3), 4.95-4.91 (1H, m, H9), 4.03 (2H, d, *J* = 4.1 Hz, H1), 3.55-3.47 (1H, m, H6), 3.39-3.30 (1H, m, H6), 2.44-2.19 (3H, m, H4 and H10), 2.37 (3H, s, TsCH₃), 1.69-1.66 (1H, m, H5), 1.37-1.14 (9H, m, H5 and H11-H14), 0.84 (9H, s, SiC(CH₃)₃), 0.81 (3H, t, *J* = 6.7 Hz, H15), 0.00 (6H, s, Si(CH₃)₂); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 143.7, 139.6, 134.8, 131.8, 129.4, 129.4, 127.8, 121.5, 63.3, 49.1, 45.0, 31.7, 29.8, 29.2, 29.0, 25.9, 25.9, 22.6, 21.5, 18.4, 14.1, -5.2; **HRMS** (ES⁺) calc. for C₂₇H₄₆O₃NSSi [M+H]⁺ 492.2962; found 492.2961.

(E)-3-((Z)-2-heptylidene-1-tosylpyrrolidin-3-yl)prop-2-en-1-ol, S9a




Prepared by General Procedure G using **S8a** (1.10 g, 2.24 mmol). The resulting crude material was purified by flash chromatography (petroleum ether / EtOAc (1:1)) to give **S9a** as a colourless oil (819 mg, 2.17 mmol, 97%); **IR** (thin film, ν_{max} / cm⁻¹) 3457, 3016, 2970, 1436, 1366, 1217, 1164, 1092, 660; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 7.62 (2H, d, *J* = 8.2 Hz, TsH), 7.23 (2H, d, *J* = 8.2 Hz, TsH), 5.41 (1H, dt, *J* = 15.3 and 5.6 Hz, H2), 5.17 (1H, dd, *J* = 15.4 and 8.3 Hz, H3), 4.92 (1H, ddd, *J* = 8.0, 6.3 and 1.8 Hz, H9), 3.99 (2H, br s, H1), 3.50 (1H, ddd, *J* = 11.6, 8.7 and 3.1 Hz, H6), 3.34 (1H, dt, *J* = 11.4 and 8.3 Hz, H6), 2.37 (3H, s, TsCH₃), 2.34-2.24 (3H, m, H10 and H4), 1.70-1.62 (1H, m, H5), 1.40-1.17 (9H, m, H5 and H11 to H14), 0.81 (3H, t, *J* = 6.7 Hz, H15); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 143.8, 139.3, 134.8, 131.3, 131.2, 129.4, 127.8, 121.6, 63.1, 49.1, 45.2, 31.7, 29.7, 29.1, 29.0, 29.0, 22.6, 21.5, 14.1; **HRMS** (ES⁺) calc. for C₂₁H₃₂O₃NS [M+H]⁺ 378.2097; found 378.2097.

(E)-3-((Z)-2-heptylidene-1-tosylpyrrolidin-3-yl)acrylaldehyde, 4a




Prepared by General Procedure I using **S9A** (260 mg, 0.69 mmol). The resulting crude material was purified by column chromatography (petroleum ether → petroleum ether / EtOAc (1:1)) to give **4a** as a light yellow oil (180 mg, 0.48 mmol, 69%); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 2925, 1720, 1689, 1355, 1165, 909, 815, 729, 659; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 9.31 (1H, d, J = 7.8 Hz, H1), 7.63 (2H, d, J = 6.8 Hz, TsH), 7.24 (2H, d, J = 6.8 Hz, TsH), 6.16 (1H, dd, J = 15.6 and 8.6 Hz, H3), 5.83 (1H, dd, J = 15.6 and 7.8 Hz, H2), 4.94 (1H, t, J = 7.1 Hz, H9), 3.65- 3.57 (1H, m, H6), 3.49-3.40 (1H, m, H6), 2.75-2.64 (1H, m, H4), 2.46-2.32 (2H, m, H10), 2.37 (3H, s, TsCH₃), 1.81-1.72 (1H, m, H5), 1.47-1.21 (9H, m, H5 and H11 to H14), 0.81 (3H, t, J = 6.2 Hz, H15); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 193.1, 155.5, 144.2, 137.5, 134.7, 133.2, 129.6, 127.8, 123.6, 49.5, 45.5, 31.6, 29.6, 29.2, 29.0, 28.6, 22.6, 21.5, 14.0; **HRMS** (ES⁺) calc. for C₂₁H₃₀O₃NS [M+H]⁺ 376.1941; found 376.1940.

(E)-3-(2-heptyl-1-tosyl-4,5-dihydro-1H-pyrrol-3-yl)acrylaldehyde, 8a




Et₃N (1.36 mL, 9.80 mmol, 10.0 equiv.), DMSO (0.97 mL, 13.7 mmol, 14.0 equiv.) and SO₃·py (935 mg, 5.88 mmol, 6.0 equiv.) were added to a solution of alcohol **S9a** (37 mg, 0.98 mmol, 1.0 equiv.) in DCM (1 mL) at 0 °C. The solution was stirred for 2 h at rt before being quenched with pH 7 phosphate buffer (20 mL). The aqueous phase was extracted with EtOAc (3 x 20 mL), then the combined organic phases were washed with brine (2 x 20 mL), dried (MgSO₄) and concentrated. The resulting crude material was purified by flash chromatography (petroleum ether → petroleum ether / EtOAc (1:1)) to give **8a** as a light yellow oil (11.5 mg, 0.030 mmol, 30%); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 2925, 2856, 1671, 1601, 1454, 1377, 1233, 1163, 1112, 1088, 813; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 9.46 (1H, d, J = 7.9 Hz, H1), 7.62 (2H, d, J = 8.3 Hz, TsH), 7.26 (2H, d, J = 8.2 Hz, TsH), 7.20 (1H, d, J = 6.8 Hz, H3), 5.76 (1H, dd, J = 15.1 and 7.9 Hz, H2), 3.86-3.74 (2H, m, H6), 2.73-2.61 (2H, m, H10), 2.42 (2H, t, J = 9.2 Hz, H9), 2.37 (3H, s, TsCH₃), 1.57 (2H, dt, J = 15.1 and 7.6 Hz, H5), 1.36-1.09 (8H, m, H11 to H14), 0.82 (3H, t, J = 6.9 Hz, H14); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 192.9, 152.0, 144.5, 135.0, 130.0, 127.1, 126.3, 119.4, 49.4, 49.4, 31.7, 29.6, 29.5, 28.9, 26.8, 26.5, 22.6, 21.6, 14.1; **HRMS** (ES⁺) calc. for C₂₁H₂₉O₃NNaS [M+Na]⁺ 398.1765; found 398.1760.

(E)-N-(6-((tert-Butyldimethylsilyl)oxy)hex-3-en-1-yl)-N-(5-chloropent-1-yn-1-yl)-4-ethylbenzene sulfonamide, 5c




Prepared by General Procedure **C** using sulfonamide **S7** (760 mg, 1.98 mmol, 1.0 equiv.) and 1-bromo-5-chloropent-1-yne (432 mg, 2.40 mmol, 1.2 equiv.). The resulting crude material was purified by column chromatography (petroleum ether / EtOAc (95:5)) to give **5c** as a colourless oil (680 mg, 1.40 mmol, 71%); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 2954, 2929, 1363, 1254, 1168, 1091, 834, 813, 775; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 7.76 (2H, d, $J = 8.2$ Hz, TsH), 7.33 (2H, d, $J = 8.1$ Hz, TsH), 5.53-5.42 (1H, m, H3), 5.39-5.26 (1H, m, H4), 3.62-3.55 (4H, m, H1 and H6), 3.28 (2H, t, $J = 7.4$ Hz, H11), 2.46 (2H, t, $J = 6.8$ Hz, H2), 2.44 (3H, s, TsCH₃), 2.29 (2H, q, $J = 7.1$ Hz, H9), 2.16 (2H, q, $J = 6.8$ Hz, H5), 1.92 (2H, quint, $J = 6.5$ Hz, H10), 0.88 (9H, s, SiC(CH₃)₃), 0.03 (6H, s, Si(CH₃)₂); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 144.4, 134.6, 130.0, 129.6, 127.5, 127.0, 74.0, 68.4, 62.9, 51.1, 43.5, 36.2, 31.5, 31.1, 25.9, 21.6, 18.3, 15.9, -5.3; **HRMS** (ES⁺) calc. for C₂₄H₃₉O₃NCI₂Si [M+H]⁺ 484.2103; found 484.2102.

(Z)-3-((E)-3-((tert-Butyldimethylsilyl)oxy)prop-1-en-1-yl)-2-(4-chlorobutylidene)-1-tosylpyrrolidine, S8b




Prepared by General Procedure **F** using ynamide **5c** (604 mg, 1.25 mmol). The crude material was purified by flash chromatography (petroleum ether / EtOAc (95:5)) to give **S8b** as a colourless oil (498 mg, 1.03 mmol, 82%); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 2954, 2929, 1598, 1471, 1329, 1253, 1091, 1067, 835, 776; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 7.62 (2H, d, $J = 9.0$ Hz, TsH), 7.24 (2H, d, $J = 7.4$ Hz, TsH), 5.35 (1H, d, $J = 14.2$ Hz, H2), 5.18 (1H, dd, $J = 15.3$ and 8.3 Hz, H3), 4.91 (1H, t, $J = 7.2$ Hz, H9), 4.04 (2H, d, $J = 2.1$ Hz, H1), 3.77-3.68 (1H, m, H6), 3.52-3.45 (2H, m, H12), 3.36 (1H, dt, $J = 18.5$ and 7.5 Hz, H6), 2.62-2.49 (2H, m, H10), 2.38 (3H, s, TsCH₃), 2.25 (1H, dd, $J = 16.9$ and 8.4 Hz, H4), 1.99-1.63 (3H, m, H5 and H11), 1.67 (1H, dd, $J = 18.4$ and 9.2 Hz, H5), 0.84 (9H, s, SiC(CH₃)₃), 0.00 (3H, s, Si(CH₃)₂); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 143.9, 141.0, 134.6, 132.1, 129.5, 129.0, 127.8, 119.0, 76.7, 63.2, 49.1, 45.2, 44.6, 32.8, 29.1, 26.6, 25.9, 21.6, -5.2; **HRMS** (ES⁺) calc. for C₂₄H₃₈O₃NCI₂NaSSi [M+Na]⁺ 506.1922; found 506.1919.

(E)-3-((Z)-2-(4-Chlorobutylidene)-1-tosylpyrrolidin-3-yl)prop-2-en-1-ol, S9b




Prepared by General Procedure **G** using **S8b** (521 mg, 1.08 mmol). The resulting crude material was purified by flash chromatography (petroleum ether / EtOAc (1:1)) to give **S9b** as a colourless oil (240 mg, 0.65 mmol, 60%); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 3450, 2925, 1449, 1348, 1160, 1120, 1015, 709; **¹H NMR** (400 MHz, CDCl₃) δ_H 7.66 (2H, d, *J* = 7.8 Hz), 7.28 (2H, d, *J* = 7.8 Hz), 5.47 (1H, dt, *J* = 14.5 and 5.3 Hz, H2), 5.21 (1H, dd, *J* = 15.3 and 8.3 Hz, H3), 4.96 (1H, t, *J* = 7.2 Hz, H9), 4.03 (2H, d, *J* = 4.9 Hz, H1), 3.53 (3H, t, *J* = 6.5 Hz, H12 and H6), 3.38 (1H, dd, *J* = 18.5 and 9.4 Hz, H6), 2.54 (2H, dd, *J* = 15.1 and 7.9 Hz, H10), 2.41 (3H, s, TsCH₃), 2.32 (1H, q, *J* = 8.4 Hz, H4), 1.96-1.68 (3H, m, H5 and H11), 1.38-1.21 (1H, m, H5); **¹³C NMR** (101 MHz, CDCl₃) δ_C 144.0, 140.7, 134.5, 131.7, 130.5, 129.5, 127.7, 119.1, 62.8, 49.1, 45.2, 44.7, 32.6, 29.0, 26.6, 21.5; **HRMS** (ES⁺) calc. for C₁₈H₂₅O₃NCIS [M+H]⁺ 370.1238; found 370.1234.

(E)-3-((Z)-2-(4-chlorobutylidene)-1-tosylpyrrolidin-3-yl)acrylaldehyde, 4b




Prepared by General Procedure **I** using **S9b** (74 mg, 0.20 mmol). The resulting crude material was purified by flash chromatography (petroleum ether → petroleum ether / EtOAc (1:1)) to give **4b** as a light yellow oil (53 mg, 0.144 mmol, 72%); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 2928, 1728, 1687, 1351, 1161, 1090, 840, 708; **¹H NMR** (400 MHz, CDCl₃) δ_H 9.37 (1H, ddd, *J* = 7.8, 2.0 and 1.0 Hz, H1), 7.67 (2H, d, *J* = 8.1 Hz, TsH), 7.31 (2H, d, *J* = 7.4 Hz, TsH), 6.22 (1H, dd, *J* = 15.6 and 8.6 Hz, H2), 5.89 (1H, dd, *J* = 16.4 and 7.8 Hz, H3), 4.99 (1H, t, *J* = 7.2 Hz, H9), 3.67 (1H, br t, *J* = 10.1 Hz, H6), 3.57-3.46 (3H, m, H6 and 2 x H12), 2.77 (1H, app q, *J* = 8.3 Hz, H4), 2.58 (2H, app q, *J* = 7.5 Hz, H10), 2.42 (3H, s, TsCH₃), 1.97-1.80 (3H, m, H5 and 2 x H11), 1.54-1.43 (1H, m, H5); **¹³C NMR** (101 MHz, CDCl₃) δ_C 193.0, 154.9, 144.4, 138.9, 134.6, 133.4, 129.7, 127.8, 121.1, 49.5, 45.6, 44.6, 32.4, 28.4, 26.9, 21.5; **HRMS** (ES⁺) calc. for C₁₈H₂₃O₃NCIS [M+H]⁺ 368.1081; found 368.1077.

(E)-N-(6-((tert-Butyldimethylsilyl)oxy)hex-3-en-1-yl)-4-methyl-N-(prop-1-yn-1-yl)benzenesulfonamide, 5d




Prepared by General Procedure **D** and **E** using sulfonamide **S7** (760 mg, 1.98 mmol). The resulting crude material was purified by flash chromatography (petroleum ether / EtOAc (95:5)) to give **5d** as a colorless oil (680 mg, 1.61 mmol, 81%); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 2954, 2857, 1362, 1253, 1168, 1092, 834, 812, 775; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 7.76 (2H, d, $J = 8.3$ Hz, TsH), 7.32 (2H, d, $J = 8.3$ Hz, TsH), 5.52-5.41 (1H, m, H3), 5.39-5.29 (1H, m, H4), 3.58 (2H, t, $J = 6.8$ Hz, H1), 3.25 (2H, t, $J = 8$ Hz, H6), 2.43 (3H, s, TsCH₃), 2.29 (2H, q, $J = 7.1$ Hz, H2), 2.16 (2H, q, $J = 6.8$ Hz, H3), 1.89 (3H, s, H9), 0.88 (9H, s, SiC(CH₃)₃), 0.03 (6H, s, Si(CH₃)₂); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 144.2, 134.8, 129.9, 129.6, 127.5, 127.2, 71.8, 70.6, 65.7, 62.9, 51.1, 36.2, 31.1, 25.9, 21.6, 3.3, -5.3; **HRMS** (ES⁺) calc. for C₂₂H₃₅O₃NNaS [M+Na]⁺ 444.1999; found 444.2000.

(Z)-3-((E)-3-((tert-Butyldimethylsilyl)oxy)prop-1-en-1-yl)-2-ethylidene-1-tosylpyrrolidine, S8c




Prepared by General Procedure **F** using ynamide **5d** (600 mg, 1.42 mmol). The crude material was purified by flash chromatography (petroleum ether / EtOAc (95:5)) to give **S8c** as colourless oil (532 mg, 1.26 mmol, 89%); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 2954, 2929, 1390, 1351, 1164, 1114, 1096, 1060, 954, 836, 770; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 7.64 (2H, d, $J = 8.2$ Hz, TsH), 7.24 (2H, d, $J = 8.1$ Hz, TsH), 5.34 (1H, dt, $J = 15.3$ and 5.0 Hz, H2), 5.19 (1H, dd, $J = 15.3$ and 8.3 Hz, H3), 5.07 (1H, qd, $J = 7.0$ and 1.9 Hz, H9), 4.03 (2H, d, $J = 4.9$ Hz, H1), 3.51 (1H, ddd, $J = 17.1$, 11.7 and 5.2 Hz, H6), 3.43-3.30 (1H, m, H6), 2.38 (3H, s, TsCH₃), 2.24 (1H, ddd, $J = 10.0$, 9.1 and 5.3 Hz, H4), 1.96 (3H, d, $J = 3.9$ Hz, H10), 1.86 (1H, dd, $J = 7.1$ and 2.1 Hz, H5), 1.66 (1H, ddt, $J = 13.5$, 8.7 and 4.3 Hz, H5), 0.84 (9H, s, SiC(CH₃)₃), -0.00 (6H, s, Si(CH₃)₂); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 143.7, 141.0, 134.7, 131.8, 129.4, 127.8, 115.5, 76.7, 63.4, 49.1, 45.1, 29.1, 25.9, 21.5, 18.4, 15.0, -5.2; **HRMS** (ES⁺) calc. for C₂₂H₃₆O₃NSSi [M+H]⁺ 422.2179; found 422.2178.

(E)-3-((Z)-2-Ethylidene-1-tosylpyrrolidin-3-yl)prop-2-en-1-ol, S9c




Prepared by General Procedure G using **S8c** (353 mg, 0.84 mmol). The resulting crude material was purified by flash chromatography (petroleum ether / EtOAc (1:1)) to give **S9c** as a colourless oil (155 mg, 0.50 mmol, 60%); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 3445, 2921, 1736, 1449, 1350, 1242, 1161, 1090, 813; **¹H NMR** (400 MHz, CDCl₃) δ_H 7.62 (2H, d, *J* = 8.0 Hz, TsH), 7.23 (2H, d, *J* = 8.0 Hz, TsH), 5.41 (1H, dt, *J* = 15.3 and 5.6 Hz, H2), 5.18 (1H, dd, *J* = 15.4 and 8.3 Hz, H3), 5.06 (1H, qd, *J* = 7.0 and 1.8 Hz, H9), 3.97 (2H, d, *J* = 5.5 Hz, H1), 3.53-3.47 (1H, m, H6), 3.37-3.30 (1H, m, H6), 2.36 (3H, s, TsCH₃), 2.25 (1H, q, *J* = 8.3 Hz, H4), 1.83 (3H, d, *J* = 6.1 Hz, H10), 1.69-1.62 (1H, m, H5), 1.37-1.18 (1H, m, H5); **¹³C NMR** (101 MHz, CDCl₃) δ_C 143.8, 140.7, 134.6, 131.4, 130.8, 129.4, 127.7, 115.5, 62.9, 49.0, 45.1, 28.9, 21.5, 15.0; **HRMS** (ES⁺) calc. for C₁₆H₂₂O₃NS [M+H]⁺ 308.1314; found 308.1313.

(E)-3-((Z)-2-Ethylidene-1-tosylpyrrolidin-3-yl)acrylaldehyde, 4c




Prepared by General Procedure I using **S9c** (50 mg, 0.16 mmol). The resulting crude material was purified by column chromatography (petroleum ether → petroleum ether / EtOAc (1:1)) to give **4c** as a light yellow oil (30 mg, 0.098 mmol, 60%); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 2923, 1796, 1724, 1687, 1551, 1401, 1350, 1191, 1158, 773; **¹H NMR** (400 MHz, CDCl₃) δ_H 9.36 (1H, d, *J* = 7.8 Hz, H1), 7.69 (2H, d, *J* = 8.2 Hz, TsH), 7.30 (2H, d, *J* = 8.2 Hz, TsH), 6.23 (1H, dd, *J* = 15.6 and 8.6 Hz, H2), 5.89 (1H, dd, *J* = 15.6 and 7.8 Hz, H3), 5.18-5.10 (1H, m, H9), 3.67 (1H, ddd, *J* = 12.3, 8.5 and 4.0 Hz, H6), 3.51 (1H, dt, *J* = 11.7, 7.9 Hz, H6), 2.75 (1H, q, *J* = 8.4 Hz, H4), 2.43 (3H, s, TsCH₃), 1.93 (3H, d, *J* = 7.1 Hz, H10), 1.88-1.78 (1H, m, H5), 1.54-1.43 (1H, m, H5); **¹³C NMR** (101 MHz, CDCl₃) δ_C 193.1, 155.4, 144.3, 139.0, 134.7, 133.2, 129.7, 127.8, 117.6, 49.5, 45.5, 28.5, 21.5, 15.2; **HRMS** (ES⁺) calc. for C₁₆H₂₀O₃NS [M+H]⁺ 306.1158; found 306.1159.

(E)-N-(6-((tert-Butyldimethylsilyl)oxy)hex-3-en-1-yl)-4-methyl-N-(phenylethynyl)benzenesulfonamide, 5e



Prepared by General Procedure C using sulfonamide **S7** (760 mg, 1.98 mmol, 1.0 equiv.) and (bromoethynyl)benzene (432 mg, 2.40 mmol, 1.2 equiv.). The resulting crude material was purified by flash chromatography (petroleum ether / EtOAc (95:5)) to give **5e** as a colourless oil (660 mg, 1.36 mmol, 69%); **IR** (thin film, ν_{max} / cm⁻¹) 2953, 2856, 2235, 1366, 1254, 1169, 1091, 733; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 7.76 (2H, d, *J* = 8.2 Hz, TsH), 7.34-7.30 (4H, m, PhH and TsH), 7.28-7.22 (3H, m, PhH), 5.51-5.44 (1H, m, H3), 5.38-5.31 (1H, m, H4), 3.55 (2H, t, *J* = 6.8 Hz, H1), 3.38 (2H, t, *J* = 7.5 Hz, H6), 2.41 (3H, s, TsCH₃), 2.35 (2H, dd, *J* = 14.4 and 7.2 Hz, H2), 2.14 (2H, q, *J* = 6.8 Hz, H5), 0.84 (9H, s, SiC(CH₃)₃), 0.0 (6H, s, Si(CH₃)₂); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 144.5, 134.6, 131.3, 130.2, 129.7, 128.2, 127.7, 127.6, 127.0, 122.9, 82.2, 70.9, 67.9, 51.3, 36.2, 31.3, 25.9, 21.6, 18.3, -5.3; **HRMS** (ES⁺) calc. for C₂₇H₃₈O₃NSSi [M+H]⁺ 484.2336; found 484.2335.


(Z)-2-Benzylidene-3-((E)-3-((tert-butyldimethylsilyl)oxy)prop-1-en-1-yl)-1-tosylpyrrolidine, S8d



(5:1)


Prepared by General Procedure F using ynamide **5e** (650 mg, 1.34 mmol, 1.0 equiv.). The crude material was purified by flash chromatography (petroleum ether / EtOAc (95:5)) to give **S8d** as a yellow oil (580 mg, 1.20 mmol, 89%); **IR** (thin film, ν_{max} / cm⁻¹) 2953, 1597, 1471, 1404, 1210, 1160, 1090, 834, 814, 731; **¹H NMR** (400 MHz, CDCl₃) δ_{H} = 7.58 (2H, d, *J* = 8.2 Hz, TsH), 7.54 (2H, d, *J* = 7.4 Hz, PhH), 7.29-7.16 (3H, m, TsH and PhH), 7.15-7.07 (2H, m, PhH), 5.85 (1H, d, *J* = 2.1 Hz, H9), 5.44 (1H, dt, *J* = 15.3 and 4.9 Hz, H2), 5.32-5.19 (1H, m, H3), 4.06 (2H, dd, *J* = 4.9 and 1.4 Hz, H1), 3.62 (1H, ddd, *J* = 15.7, 9.4 and 5.1 Hz, H6), 3.45 (1H, ddd, *J* = 14.6, 10.4 and 7.5 Hz, H6), 2.49 (1H, q, *J* = 10.2 Hz, H4), 2.35 (3H, s, TsCH₃), 1.77-1.69 (1H, m, H5), 1.35 (1H, ddd, *J* = 19.5, 12.3 and 9.1 Hz, H5), 0.83 (9H, s, SiC(CH₃)₃), 0.00 (6H, s, Si(CH₃)₂); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 143.9, 140.6, 136.4, 134.5, 132.6, 129.4, 129.2, 128.8, 127.9, 127.7, 126.8, 118.8, 63.4, 49.1, 46.3, 28.8, 25.9, 25.9, 21.6, -5.2; **HRMS** (ES⁺) calc. for C₂₇H₃₈O₃NSSi [M+H]⁺ 484.2336; found 484.2334.

(E)-3-((Z)-2-Benzylidene-1-tosylpyrrolidin-3-yl)prop-2-en-1-ol, S9d



Prepared by General Procedure **G** using **S8d** (300 mg, 0.62 mmol). The resulting crude material was purified by flash chromatography (petroleum ether / EtOAc (1:1)) to give **S9d** as a yellow oil (140 mg, 0.38 mmol, 61%); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 3385, 2958, 2899, 1597, 1305, 1160, 1088, 911, 756; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 7.61 (2H, d, $J = 8.1$ Hz, TsH), 7.57 (2H, d, $J = 7.4$ Hz, PhH), 7.24 (4H, m, TsH and PhH), 7.14 (1H, t, $J = 7.4$ Hz, PhH), 5.90 (1H, d, $J = 1.8$ Hz, H9), 5.54 (1H, dt, $J = 14.6$ and 5.2 Hz, H2), 5.31 (1H, dd, $J = 15.3$ and 8.4 Hz, H3), 4.04 (2H, br s, H1), 3.75-3.62 (1H, m, H6), 3.49 (1H, dd, $J = 19.5$ and 8.4 Hz, H6), 2.56 (1H, q, $J = 8.6$ Hz, H4), 2.38 (3H, s, TsCH₃), 1.95 (1H, br s, OH), 1.77 (1H, dd, $J = 18.6$ and 8.6 Hz, H5), 1.46 - 1.36 (1H, m, H5); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 144.0, 140.4, 136.2, 134.3, 132.1, 130.4, 129.4, 128.7, 127.8, 127.6, 126.7, 118.8, 62.8, 49.1, 46.1, 28.6, 21.5; **HRMS** (ES⁺) calc. for C₂₁H₂₃O₃NNaS [M+Na]⁺ 392.1291; found 392.1289.


(E)-3-((Z)-2-benzylidene-1-tosylpyrrolidin-3-yl)acrylaldehyde, 4d




Prepared by General Procedure **I** using **S9d** (70 mg, 0.19 mmol, 1.0 equiv.). The resulting crude material was purified by flash chromatography (petroleum ether -> petroleum ether / EtOAc (1:1)) to give **4d** as a yellow oil (46 mg, 0.13 mmol, 66%); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 3016, 1728, 1685, 1598, 1353, 1158, 1089, 1030, 815; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 9.37 (1H, d, $J = 7.8$ Hz, H1), 7.57 (2H, d, $J = 8.3$ Hz, TsH), 7.51 (2H, d, $J = 7.3$ Hz, PhH), 7.21 (4H, m, TsH and PhH), 7.12 (1H, t, $J = 7.3$ Hz, PhH), 6.31 (1H, dd, $J = 15.6$ and 8.8 Hz, H2), 5.95 (1H, dd, $J = 15.6$ and 7.8 Hz, H3), 5.84 (1H, d, $J = 1.7$ Hz, H9), 3.74 (1H, ddd, $J = 12.2$, 8.4 and 4.0 Hz, H6), 3.56 (1H, dt, $J = 11.9$ and 7.9 Hz, H6), 2.96 (1H, q, $J = 8.6$ Hz, H4), 2.35 (3H, s, TsCH₃), 1.89-1.81 (1H, m, H5), 1.56-1.46 (1H, m, H5); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 193.0, 155.0, 144.4, 138.4, 135.6, 134.4, 133.7, 129.6, 128.8, 127.9, 127.8, 127.3, 120.6, 49.6, 46.4, 28.3, 21.5; **HRMS** (ES⁺) calc. for C₂₁H₂₂O₃NS [M+H]⁺ 368.1315; found 368.1318.

1.3.4 Cycloaddition reactions of dienals **4a-d**

4a-d were reacted with the following dienophiles:





(3'S,4S,6S,7S)-1'-*tert*-Butyl 6-ethyl 7-hexyl-2'-oxo-4-(2-oxoethyl)-1-tosyl-1,2,3,4,6,7-hexahydrospiro[indole-5,3'-indoline]-1',6-dicarboxylate, 12a




Prepared by General Procedure K using catalyst (*S*)-10 (3.2 μ L, 0.010 mmol, 0.2 equiv.), 4a (28 mg, 0.075 mmol, 1.5 equiv.) and olefinic oxindole 9a (15.8 mg, 0.050 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave cycloadduct 12a as a light yellow oil (27 mg, 0.039 mmol, 78%); $[\alpha]_D^{25} -94.3$ ($c = 1.0$, CHCl₃); IR (thin film, ν_{max} / cm⁻¹) 2128, 1750, 1730, 1605, 1464, 1353, 1304, 1253, 1162; ¹H NMR (400 MHz, CDCl₃) δ _H 9.67 (1H, s, H15), 7.94 (2H, d, $J = 8.0$ Hz, TsH), 7.81 (1H, d, $J = 7.9$ Hz, ArH), 7.40 (2H, d, $J = 8.0$ Hz, TsH), 7.21 (1H, td, $J = 8.0$ and 1.4 Hz, ArH), 6.63 (1H, t, $J = 8.0$ Hz, ArH), 6.55 (1H, d, $J = 6.5$ Hz, ArH), 4.03 (1H, ddd, $J = 11.7$, 8.0 and 6.4 Hz, H2), 3.83-3.78 (3H, m, H2 and OCH₂CH₃), 3.67 (1H, br s, H7), 3.33 (1H, dd, $J = 18.6$ and 8.9 Hz, H14), 3.27 (1H, d, $J = 7.1$ Hz, H6), 2.89 (1H, d, $J = 8.6$ Hz, H4), 2.51 (3H, s, TsCH₃), 2.28 (1H, dd, $J = 18.7$ and 3.0 Hz, H14), 2.24-2.19 (2H, m, H3), 2.00-1.93 (1H, m, H8), 1.81-1.93 (1H, m, H8), 1.60 (9H, s, C(CH₃)₃), 1.37-1.14 (8H, m, H9-H12), 0.89 (6H, t, $J = 7.1$ Hz, OCH₂CH₃ and H13); ¹³C NMR (101 MHz, CDCl₃) δ _C 198.9, 176.7, 171.0, 148.9, 144.0, 139.3, 138.8, 136.2, 130.5, 130.1, 128.4, 128.1, 123.8, 123.5, 123.3, 114.7, 84.14, 61.2, 51.6, 50.1, 47.7, 44.3, 37.4, 33.8, 33.5, 31.8, 30.3, 29.5, 27.9, 25.4, 22.7, 21.6, 14.1, 13.4; HRMS (ES⁺) calc. for C₃₈H₄₈O₈N₂NaS [M+Na]⁺ 715.3023; found 715.3018.

Chiralpak IB (25% IPA in hexane, flow rate = 1.0 mL/min, 230 nm) t_R major – 6.1 min, minor – 7.3 min (94% ee).




(3'S,4S,6S,7S)-1'-*tert*-Butyl 6-ethyl 7-(3-chloropropyl)-2'-oxo-4-(2-oxoethyl)-1-tosyl-1,2,3,4,6,7-hexahydrospiro[indole-5,3'-indoline]-1',6-dicarboxylate, 12b




Prepared by General Procedure **K** using catalyst (*S*)-**10** (3.2 μ L, 0.010 mmol, 0.2 equiv.), **4b** (27.5 mg, 0.075 mmol, 1.5 equiv.) and olefinic oxindole **9a** (15.8 mg, 0.05 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave cycloadduct **12b** as a colourless oil (23 mg, 0.034 mmol, 67%); $[\alpha]_D^{25} -51.3$ ($c = 0.5$, CHCl₃); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 2927, 2856, 1787, 1755, 1726, 1598, 1482, 1348, 1250; **¹H NMR** (500 MHz, CDCl₃) δ = 9.67 (1H, s, H12), 7.93 (2H, d, $J = 8.0$ Hz, TsH), 7.82 (1H, d, $J = 8.1$ Hz, ArH), 7.41 (2H, d, $J = 8.0$ Hz, TsH), 7.22 (1H, dt, $J = 15.1$ and 4.1 Hz, ArH), 6.64 (1H, t, $J = 7.9$ Hz, ArH), 6.54 (1H, d, $J = 7.0$ Hz, ArH), 4.16-4.10 (1H, m, H2), 4.05-3.99 (1H, m, H2), 3.85-3.78 (2H, m, OCH₂CH₃), 3.74-3.70 (1H, m, H7), 3.62-3.53 (2H, m, H10), 3.30 (1H, dd, $J = 18.6$ and 8.7 Hz, H11), 3.23 (1H, d, $J = 7.1$ Hz, H6), 2.92 (1H, d, $J = 6.5$ Hz, H4), 2.52 (3H, s, TsCH₃), 2.29 (1H, dd, $J = 18.7$ and 3.1 Hz, H11), 2.23 (2H, td, $J = 9.1$ and 2.4 Hz, H3), 2.16-2.10 (1H, m, H8), 1.99-1.83 (2H, m, H9), 1.75-1.66 (1H, m, H8), 1.61 (9H, s, C(CH₃)₃), 0.90 (3H, t, $J = 7.1$ Hz, OCH₂CH₃); **¹³C NMR** (126 MHz, CDCl₃) δ = 198.7, 176.5, 170.9, 148.9, 144.3, 138.9, 138.6, 135.9, 130.3, 130.1, 128.6, 128.1, 124.3, 123.9, 123.2, 114.8, 84.3, 61.4, 51.6, 50.0, 47.7, 44.8, 44.2, 37.2, 33.1, 31.6, 30.3, 29.0, 28.0, 21.7, 13.4; **HRMS** (ES⁺) calc. for C₃₅H₄₂O₈N₂CIS [M+H]⁺ 685.2344; found 685.2338.

Chiralpak IB (20% IPA in hexane, flow rate = 1.0 mL/min, 254 nm) t_R major: 11.2 min, minor: 13.6 min (97% ee).





(3'S,4S,6S,7S)-1'-*tert*-Butyl 6-ethyl 7-methyl-2'-oxo-4-(2-oxoethyl)-1-tosyl-1,2,3,4,6,7-hexahydrospiro[indole-5,3'-indoline]-1',6-dicarboxylate, 12c




Prepared by General Procedure **K** using catalyst (*S*)-**10** (3.2 μ L, 0.010 mmol, 0.2 equiv.), **4c** (22.8 mg, 0.075 mmol, 1.5 equiv.) and olefinic oxindole **9a** (15.8 mg, 0.05 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave cycloadduct **12c** as a light yellow oil (23 mg, 0.036 mmol, 74%); $[\alpha]_D^{25} -57.1$ ($c = 0.8$, CHCl₃); IR (thin film, ν_{max} / cm⁻¹) 2922, 2850, 1764, 1722, 1602, 1475, 1348, 1306, 1156, 986, 739; ¹H NMR (500 MHz, CDCl₃) δ _H 9.67 (1H, s, H10), 7.92 (2H, d, $J = 8.0$ Hz, TsH), 7.80 (1H, d, $J = 8.2$ Hz, ArH), 7.41 (2H, d, $J = 8.0$ Hz, TsH), 7.25-7.21 (1H, m, ArH), 6.69 (1H, t, $J = 8.0$ Hz, ArH), 6.63 (1H, d, $J = 8.5$ Hz, ArH), 4.06 (1H, ddd, $J = 11.9, 9.1$ and 4.8 Hz, H2), 3.88-3.77 (3H, m, H2 and OCH₂CH₃), 3.53-3.50 (1H, m, H7), 3.32 (1H, dd, $J = 18.6$ and 8.9 Hz, H9), 3.09 (1H, d, $J = 8.1$ Hz, H6), 2.87 (1H, d, $J = 7.0$ Hz, H4), 2.51 (3H, s, TsCH₃), 2.31 (1H dd, $J = 18.7$ and 3.0 Hz, H9), 2.29-2.17 (2H, m, H3), 1.60 (9H, s, C(CH₃)₃), 1.50 (3H, d, $J = 6.5$ Hz, H8), 0.94 (3H, t, $J = 7.1$ Hz, OCH₂CH₃); ¹³C NMR (126 MHz, CDCl₃) δ _C 198.9, 176.6, 170.8, 148.8, 144.2, 140.4, 138.9, 136.2, 130.6, 130.1, 128.4, 128.0, 123.9, 123.1, 123.0, 114.8, 84.2, 61.2, 51.2, 51.0, 50.2, 44.1, 37.7, 30.3, 29.7, 28.0, 21.7, 21.7, 13.5; HRMS (ES⁺) calc. for C₃₃H₃₉O₈N₂S [M+H]⁺ 623.2421; found 623.2433.


Chiralpak IB (20% IPA in hexane, flow rate = 1.0 mL/min, 230 nm) t_R major: 12.2 min, minor: 18.9 min (98% ee).



Proof of stereochemistry for oxindole cycloadditions: Cycloadduct **12c** was used to assign the relative stereochemistry of the cycloaddition through ^1H NMR nOe experiments (1D nOe / 2D NOESY). On the alpha face (as depicted below), a strong enhancement was seen between H6 and H8 (side chain methyl), indicating these groups to be on the same face; on the beta face, a strong enhancement was seen between H4 and an aryl proton.





(3'S,4S,6S,7R)-1'-*tert*-Butyl 6-ethyl 2'-oxo-4-(2-oxoethyl)-7-phenyl-1-tosyl-1,2,3,4,6,7-hexahydrospiro[indole-5,3'-indoline]-1',6-dicarboxylate, 12d




Prepared by General Procedure **K** using catalyst (*S*)-**10** (3.2 μL , 0.01 mmol, 0.2 equiv.), **4d** (27.5 mg, 0.075 mmol, 1.5 equiv.) and olefinic oxindole **9a** (15.8 mg, 0.05 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave cycloadduct **12d** as a yellow oil (24 mg, 0.035 mmol, 70% yield); $[\alpha]_D^{25} -57.4$ ($c = 1.1$, CHCl_3); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 2928, 1789, 1757, 1726, 1602, 1478, 1251, 1150, 1022, 868; **^1H NMR** (400 MHz, CDCl_3) δ_{H} 9.66 (1H, s, H9), 7.77 (1H, d, $J = 8.3$ Hz, ArH), 7.34-7.22 (3H, m, TsH and ArH), 7.23-6.91 (9H, m, TsH and ArH), 4.82-4.70 (1H, m, H2), 4.10-4.04 (1H, m, H2), 3.74-3.65 (2H, m, OCH_2CH_3), 3.63-3.52 (2H, m, H8 and H6), 3.27 (1H, d, $J = 8.9$ Hz, H7), 3.02 (1H, dd, $J = 11.3$ and 7.9 Hz, H8), 2.56-2.40 (2H, m, H4 and H5), 2.37-2.28 (1H, m, H5), 2.32 (3H, s, TsCH_3), 1.52 (9H, s, $\text{C}(\text{CH}_3)_3$), 0.76 (3H, t, $J = 7.1$ Hz, OCH_2CH_3); **^{13}C NMR** (101 MHz, CDCl_3) δ_{C} 198.9, 176.0, 170.3, 148.7, 143.5, 141.5, 138.8, 138.1, 136.6, 130.1, 129.5, 128.7, 128.4, 128.3, 127.5, 126.9, 125.5, 124.6, 123.6, 114.8, 84.2, 61.1, 52.2, 51.8, 49.6, 44.3, 40.8, 37.9, 31.0, 28.0, 21.5, 13.4; **HRMS** (ES $^+$) calc. for $\text{C}_{38}\text{H}_{41}\text{O}_8\text{N}_2\text{S}$ $[\text{M}+\text{H}]^+$ 685.2578; found 685.2562.

HPLC data is on the next page.

Chiralpak IA (20% IPA in hexane, flow rate = 1.0 mL/min, 230 nm) Minor diastereomer: $t_{R\text{major}}$ – 11.7 min, minor – 5.2 min; Major diastereomer: $t_{R\text{major}}$ – 10.1 min, minor – 22.2 min. (95% ee).





(3'S,4S,6S,7S)-1'-*tert*-Butyl 6-ethyl 5'-chloro-7-hexyl-2'-oxo-4-(2-oxoethyl)-1-tosyl-1,2,3,4,6,7-hexahydrospiro[indole-5,3'-indoline]-1',6-dicarboxylate, 12e




Prepared by General Procedure **K** using catalyst (*S*)-**10** (3.2 μ L, 0.01 mmol, 0.2 equiv.), **4a** (28 mg, 0.075 mmol, 1.5 equiv.) and olefinic oxindole **9b** (17.5 mg, 0.050 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave cycloadduct **12e** as a light yellow oil (27 mg, 0.037 mmol, 75%); $[\alpha]_D^{25} -68.2$ ($c=0.7$, CHCl₃); **IR** (thin film, ν_{max} / cm⁻¹) 2957, 2856, 1790, 1760, 1728, 1598, 1471, 1394, 1250, 1152, 1090, 1023, 815; **¹H NMR** (400 MHz, CDCl₃) δ _H 9.66 (1H, s, H15), 7.91 (2H, d, $J = 8.1$ Hz, TsH), 7.83 (1H, d, $J = 8.7$ Hz, ArH), 7.38 (2H, d, $J = 8.1$ Hz, TsH), 7.27 (1H, dd, $J = 8.3$ and 2.6 Hz, ArH), 7.16 (1H, d, $J = 2.2$ Hz, ArH), 3.93-3.84 (3H, m, H2 and OCH₂CH₃), 3.69-3.61 (2H, m, H2 and H7), 3.25 (2H, dt, $J = 8.8$ and 7.3 Hz, H6 and H14), 2.98 (1H, d, $J = 7.7$ Hz, H4), 2.44 (3H, s, TsCH₃), 2.33 (1H, dd, $J = 18.8$ and 2.9 Hz, H14), 2.25-2.13 (2H, m, H3), 1.94-1.86 (1H, m, H8), 1.82-1.70 (1H, m, H8), 1.60 (9H, s, C(CH₃)₃), 1.36-1.23 (8H, m, H9 to H12), 0.96 (3H, t, $J = 7.1$ Hz, OCH₂CH₃), 0.89 (3H, t, $J = 6.8$ Hz, H13); **¹³C NMR** (101 MHz, CDCl₃) δ _C 198.7, 176.1, 171.0, 148.7, 144.3, 139.8, 137.5, 135.5, 132.5, 130.1, 129.7, 128.6, 127.9, 124.5, 123.5, 116.0, 84.5, 61.3, 51.8, 49.8, 47.3, 44.2, 37.1, 34.2, 32.8, 31.7, 30.5, 29.4, 28.0, 24.9, 22.6, 21.6, 14.1, 13.5; **HRMS** (ES⁻) calc. for C₃₈H₄₆O₈N₂SCI [M-H]⁻ 725.2669; found 725.2682.

Chiralpak IB (20% IPA in hexane, flow rate = 1.0 mL/min, 230 nm) t_R major – 6.1 min, minor – 7.8 min (95% ee).




(3'S,4S,6S,7S)-1'-*tert*-Butyl 6-ethyl 7-hexyl-5'-methoxy-2'-oxo-4-(2-oxoethyl)-1-tosyl-1,2,3,4,6,7-hexahydrospiro[indole-5,3'-indoline]-1',6-dicarboxylate, 12f




Prepared by General Procedure **K** using catalyst (*S*)-**10** (3.2 μ L, 0.01 mmol, 0.2 equiv.), **4a** (28 mg, 0.075 mmol, 1.5 equiv.) and olefinic oxindole **9b** (17.3 mg, 0.05 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave cycloadduct **12f** as a red oil (24 mg, 0.033 mmol, 67%); $[\alpha]_D^{25} -64.6$ ($c = 1.0$, CHCl₃); **IR** (thin film, ν_{max} / cm⁻¹) 2928, 2856, 1787, 1754, 1724, 1598, 1486, 1471, 1249, 1152, 814; **¹H NMR** (400 MHz, CDCl₃) δ _H 9.67 (1H, s, H15), 7.89 (2H, d, $J = 8.2$ Hz, TsH), 7.77 (1H, d, $J = 8.9$ Hz, ArH), 7.36 (2H, d, $J = 8.1$ Hz, TsH), 6.89 (1H, d, $J = 2.6$ Hz, ArH), 6.81 (1H, dd, $J = 8.9$ and 2.6 Hz, ArH), 3.96 (1H, ddd, $J = 11.7$, 9.0 and 2.9 Hz, H2), 3.91-3.83 (2H, m, H14), 3.80 (3H, s, OCH₃), 3.70 (1H, br s, H2), 3.54 (1H, app q, $J = 10.7$ Hz, H7), 3.30 (1H, dd, $J = 18.6$ and 8.8 Hz, H14), 3.22 (1H, d, $J = 8.1$ Hz, H6), 3.01 (1H, d, $J = 7.6$ Hz, H4), 2.45 (3H, s, TsCH₃), 2.40-2.30 (1H, m, H3), 2.32 (1H, dd, $J = 18.6$ and 3.0 Hz, H14), 2.15-2.09 (1H, m, H3), 1.81-1.76 (2H, m, H8), 1.60 (9H, s, C(CH₃)₃), 1.33-1.24 (8H, m, H9 to H12), 0.95 (3H, t, $J = 7.1$ Hz, H15), 0.88 (3H, t, $J = 6.8$ Hz, H13); **¹³C NMR** (101 MHz, CDCl₃) δ _C 198.9, 176.7, 171.1, 156.8, 149.0, 144.0, 139.4, 136.1, 132.1, 131.8, 129.9, 127.8, 125.8, 115.5, 113.3, 110.1, 83.8, 61.1, 56.0, 51.8, 49.9, 47.1, 44.3, 37.4, 34.2, 32.1, 31.7, 30.8, 29.5, 28.0, 24.6, 22.6, 21.6, 14.1, 13.5; **HRMS** (ES⁺) calc. for C₃₉H₅₀O₉N₂NaS [M+H]⁺ 745.3129; found 745.3130.

Chiralpak IB (20% IPA in hexane, flow rate = 1.0 mL/min, 210 nm) t_{R} major – 6.7 min, minor – 12.2 min (94% ee).





(3'S,4S,6S,7S)-di-*tert*-Butyl 7-methyl-2'-oxo-4-(2-oxoethyl)-1-tosyl-1,2,3,4,6,7-hexahydrospiro[indole-5,3'-indoline]-1',6-dicarboxylate, 12g




Prepared by General Procedure k using catalyst (S)-**10** (3 μ L, 0.010 mmol, 0.2 equiv.), **4c** (22.8 mg, 0.075 mmol, 1.5 equiv.) and olefinic oxindole **9d** (17.2 mg, 0.050 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave cycloadduct **12g** as a light yellow oil (25 mg, 0.038 mmol, 76%); $[\alpha]_D^{25} -98.0$ ($c = 1.0$, CHCl₃); IR (thin film, ν_{max} / cm⁻¹) 2923, 1790, 1759, 1723, 1394, 1296, 1152; ¹H NMR (400 MHz, CDCl₃) δ _H 9.67 (1H, s, H10), 7.94 (2H, d, $J = 8.0$ Hz, TsH), 7.82 (1H, d, $J = 7.9$ Hz, ArH), 7.40 (2H, d, $J = 8.0$ Hz, TsH), 7.21 (1H, td, $J = 8.2$ and 1.3 Hz, ArH), 6.63 (1H, td, $J = 7.6$ and 0.9 Hz, ArH), 6.48 (1H, dd, $J = 7.6$ and 0.8 Hz, ArH), 4.03 (1H, dt, $J = 11.7$ and 7.3 Hz, H2), 3.89-3.79 (1H, m, H2), 3.63-3.55 (1H, m, H7), 3.34 (1H, dd, $J = 18.6$ and 9.0 Hz, H9), 3.00 (1H, d, $J = 7.6$ Hz, H6), 2.83 (1H, dd, $J = 8.7$ and 1.8 Hz, H4), 2.51 (3H, s, TsCH₃), 2.28 (1H, dd, $J = 18.7$ and 2.9 Hz, H9), 2.24-2.18 (2H, m, H3), 1.59 (9H, s, C(CH₃)₃), 1.46 (3H, d, $J = 6.6$ Hz, H8), 1.06 (9H, s, C(CH₃)₃); ¹³C NMR (101 MHz, CDCl₃) δ _C 199.0, 176.5, 169.5, 148.9, 148.1, 144.1, 140.7, 138.9, 136.2, 130.8, 130.1, 128.3, 128.1, 123.8, 123.1, 122.3, 114.7, 84.1, 81.9, 51.5, 51.3, 50.1, 44.2, 37.9, 30.2, 29.1, 28.0, 27.2, 21.9, 21.7; HRMS (ES⁺) calc. for C₃₅H₄₂O₈N₂NaS [M+Na]⁺ 673.2559; found 673.2553.

Chiralpak IA (15% IPA in hexane, flow rate = 1.3 mL/min, 254 nm) t_R major: 8.4 min, minor: 6.6 min (89% ee).





(3S,4'S,6'S,7'S)- and (3R,4'S,6'R,7'S)-Ethyl 7'-methyl-2-oxo-4'-(2-oxoethyl)-1'-tosyl-1',2',3',4',6',7'-hexahydro-2H-spiro[benzofuran-3,5'-indole]-6'-carboxylate, 18a and 18b




Prepared by General Procedure **K** using catalyst (*S*)-**10** (3.2 μ L, 0.010 mmol, 0.2 equiv.), **4c** (22.8 mg, 0.075 mmol, 1.5 equiv.) and olefinic lactone **17** (10.9 mg, 0.05 mmol, 1.0 equiv.). Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave cycloadducts **18a** and **18b** (dr: 1:1) as a colourless oil (20 mg, 0.038 mmol, 77% yield); $[\alpha]_D^{25} -6.02$ ($c = 1.0$, CHCl₃); **IR** (thin film, ν_{max} / cm⁻¹) 2924, 1796, 1723, 1461, 1348, 1161; **¹H NMR** (400 MHz, CDCl₃) δ _H 9.71 (1H, s, H10), 9.42 (1H, s, H10), 7.91 (2H, d, $J = 8.2$ Hz, TsH), 7.70 (1H, d, $J = 8.2$ Hz, TsH), 7.42-7.34 (5H, m, TsH and ArH), 7.27-7.18 (4H, m, TsH and ArH), 7.13-7.06 (2H, m, ArH), 6.75 (1H, t, $J = 7.9$ Hz, ArH), 6.66 (1H, d, $J = 7.6$ Hz, ArH), 4.16-4.06 (4H, m, OCH₂CH₃), 3.97-3.90 (4H, m, H2), 3.82-3.73 (2H, m, H7), 3.49-3.35 (3H, m, H9 and H4), 3.11-2.95 (3H, m, H4 and H6), 2.51 (3H, s), 2.50 (3H, s), 2.42 (2H, dd, $J = 18.8$ and 3.5 Hz, H9), 2.35-2.20 (2H, m, H3), 1.96-1.72 (2H, m, H3), 1.50 (3H, d, $J = 6.5$ Hz, H8), 1.33 (3H, d, $J = 7.1$ Hz, H8), 1.27-1.21 (3H, m, OCH₂CH₃), 1.01 (3H, t, $J = 7.1$ Hz, OCH₂CH₃); **¹³C NMR** (101 MHz, CDCl₃) δ _C 198.8, 198.3, 179.2, 177.6, 170.5, 170.4, 154.4, 152.7, 144.5, 144.3, 140.6, 140.5, 136.3, 134.2, 130.1, 130.1, 129.8, 129.7, 129.2, 128.0, 127.2, 126.1, 125.8, 124.6, 124.0, 123.8, 123.6, 123.2, 111.2, 110.8, 61.6, 60.4, 52.9, 51.4, 51.0, 50.3, 50.2, 50.1, 44.2, 43.5, 38.1, 37.2, 30.7, 30.5, 30.4, 29.9, 21.7, 21.3, 14.6, 14.2, 14.0, 13.6; **HRMS** (ES⁺) calc. for C₂₈H₂₉O₇NNaS [M+Na]⁺ 546.1562; found 546.1562.

Chiralpak IA (10% IPA in hexane, flow rate = 1.3 mL/min, 230 nm) t_R major: 15.8 min, minor: 17.7 min, and t_R major: 19.7 min, minor: 29.6 min (93% ee & 89% ee).




1.3.5 Synthesis of dienals **3b** and **4e**

3b was synthesized according to the following scheme:




(*S*)-2-phenylbut-3-en-1-ol, **S10**




S10 was prepared according to the procedure of Tan *et al.*⁶ To a solution of (*R*)-phenyloxirane (1.00 g, 8.32 mmol, 1.0 equiv.) and Cu(COD)Cl (172 mg, 0.83 mmol, 0.1 equiv.) in THF (12 mL) at $-78\text{ }^{\circ}\text{C}$ was added vinylmagnesium bromide (10.0 mL, 10.0 mmol, 1.0 M solution in THF,). The reaction was allowed to warm to rt over 8 h, then it was quenched by the addition of NH₄Cl (30 mL, sat., aq.) and extracted with EtOAc (3 x 40 mL). The combined organics were dried (MgSO_4), and concentrated. The crude residue was purified by flash chromatography (petroleum ether / EtOAc (90:10)) to afford **S10** as a colourless oil (870 mg, 5.87 mmol, 71%); $[\alpha]_D^{25} +67.3$ ($c = 1.0$, CHCl₃); *IR*: +67.5 ($c = 0.545$, CHCl₃); *IR* (thin film, ν_{max} / cm⁻¹) 3448, 3028, 1493, 1452, 1055, 1026, 992, 916, 756; ¹**H NMR** (400 MHz, CDCl₃) δ_{H} 7.25 (2H, t, $J = 7.3$ Hz, PhH), 7.18-7.14 (3H, m, PhH), 5.99-5.85 (1H, m, H3), 5.16-5.04 (2H, m, H4), 3.72 (2H, d, $J = 7.1$ Hz H1), 3.43 (1H, app q, $J = 7.3$ Hz, H2), 1.64 (1H, br s, OH); ¹³**C NMR** (101 MHz, CDCl₃) δ_{C} 140.8, 138.3, 128.8, 128.0, 127.0, 117.1, 66.1, 52.6. Data identical to literature values.⁶

(S)-methyl (2-phenylbut-3-en-1-yl)(tosyl)carbamate, S11




Prepared by General Procedure **A** using alcohol **S10** (1.00 g, 6.75 mmol, 1.0 equiv.). The resulting crude material was purified by flash chromatography (petroleum ether / Et₂O (9:1)) to give **S11** as a colourless oil (1.70 g, 4.73 mmol, 70%); $[\alpha]_D^{25} +9.56$ ($c = 1.0$, CHCl₃); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 2957, 2923, 1728, 1597, 1551, 1350, 1290, 1163, 1088, 764; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 7.63 (2H, d, $J = 8.4$ Hz, TsH), 7.26 (3H, t, $J = 6.2$ Hz, TsH and PhH), 7.21-7.17 (4H, m, PhH), 6.00 (1H, ddd, $J = 16.9, 10.4$ and 8.6 Hz, H3), 5.12-5.01 (2H, m, H4), 4.06 (2H, dd, $J = 14.6$ and 7.8 Hz, H1), 3.77 (1H, d, $J = 8.4$ Hz, H2), 3.52 (3H, s, CO₂CH₃), 2.34 (3H, s, TsCH₃); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 153.1, 144.7, 140.9, 138.1, 136.7, 129.4, 128.8, 128.6, 128.2, 127.1, 117.5, 53.7, 51.8, 50.4, 21.8; **HRMS** (ES⁺) calc. for C₁₉H₂₁NNaO₄S [M+Na]⁺ 382.1080; found 382.1079.

(S)-4-methyl-N-(2-phenylbut-3-en-1-yl)benzenesulfonamide, S12, and (S)-N-(4-((tert-butylidimethylsilyl)oxy)but-1-yn-1-yl)-4-methyl-N-(2-phenylbut-3-en-1-yl)benzenesulfonamide, 5f




S12 was prepared by General Procedure **B** using (S)-methyl (2-phenylbut-3-en-1-yl)(tosyl)carbamate, **S11** (1.12 g, 3.12 mmol); the sulfonamide was obtained in quantitative yield. **S12** (750 mg, 2.49 mmol, 1.0 equiv.) was then converted to **5f** using General Procedure **C** and ((4-bromobut-3-yn-1-yl)oxy)(tert-butyl)dimethylsilane (979 mg, 3.74 mmol, 1.5 equiv.). The resulting crude material was purified by flash chromatography (petroleum ether / EtOAc (90:10)) to give **5f** as a colourless oil (740 mg, 1.53 mmol, 62%); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$); $[\alpha]_D^{25} +5.94$ ($c = 0.9$, CHCl₃); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 2955, 2855, 1677, 1471, 1364, 1254, 1169, 1106, 1058, 916, 835; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 7.60 (2H, d, $J = 8.2$ Hz, TsH), 7.26-7.15 (5H, m, TsH and PhH), 7.12 (2H, d, $J = 7.0$ Hz, PhH), 5.92 (1H, ddd, $J = 17.5, 10.4$ and 7.5 Hz, H8), 5.06 (2H, dd, $J = 13.7$ and 8.2 Hz, H9), 3.69 (1H, app q, $J = 7.6$ Hz, H7), 3.61-3.53 (3H, m, H1 and H6), 3.40 (1H, dd, $J = 12.5$ and 7.2 Hz, H6), 2.41 (2H, t, $J = 7.2$ Hz, H2), 2.36 (3H, s, TsCH₃), 0.83 (10H, s, SiC(CH₃)₃), 0.00 (6H, s, Si(CH₃)₂); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 144.4, 140.4, 137.8, 134.7, 129.7, 128.7, 128.2, 127.8, 127.1, 117.2, 74.0, 68.0, 62.3, 55.5, 48.1, 26.0, 23.1, 21.7, 18.4, -5.1; **HRMS** (ES⁺) calc. for C₂₇H₃₇O₃NNaSSi [M+Na]⁺ 506.2155; found 506.2149.

(R,Z)-2-(3-((*tert*-butyldimethylsilyl)oxy)propylidene)-3-methylene-4-phenyl-1-tosylpyrrolidine, S13




Prepared by General Procedure F using ynamide **5f** (300 mg, 0.62 mmol, 1.0 equiv.). The crude material was purified by flash chromatography (petroleum ether / EtOAc (90:10)) to give **S13** as a colourless oil (256 mg, 0.53 mmol, 85%); $[\alpha]_D^{25} +102.9$ ($c = 0.8$, CHCl₃); IR (thin film, ν_{max} / cm⁻¹) 2955, 1471, 1358, 1254, 1165, 1090, 834; ¹H NMR (400 MHz, CDCl₃) δ _H 7.75 (2H, d, $J = 8.3$ Hz, TsH), 7.31 (2H, d, $J = 8.1$ Hz, TsH), 7.28-7.17 (3H, m, PhH), 6.90 (2H, d, $J = 6.4$ Hz, PhH), 6.13-6.05 (1H, m, H3), 5.34 (1H, d, $J = 3.2$ Hz, H9), 4.35 (1H, d, $J = 2.7$ Hz, H9), 4.14-3.99 (1H, m, H7), 3.81 (2H, td, $J = 6.0$ and 2.0 Hz, H1), 3.26 (1H, dd, $J = 12.8$ and 10.9 Hz, H6), 2.93-2.73 (3H, m, H6 and H2), 2.47 (3H, s, TsCH₃), 0.93 (9H, s, SiC(CH₃)₃), 0.10 (6H, s, Si(CH₃)₂); ¹³C NMR (101 MHz, CDCl₃) δ _C 148.3, 144.2, 140.6, 138.1, 136.0, 129.8, 128.7, 128.5, 128.0, 127.7, 127.2, 118.6, 106.0, 62.7, 56.9, 47.2, 33.5, 26.1, 21.8, -5.0; HRMS (ES⁺) calc. for C₂₇H₃₇O₃NNaSSi [M+Na]⁺ 506.2155; found 506.2150.

(R,Z)-3-(3-methylene-4-phenyl-1-tosylpyrrolidin-2-ylidene)propan-1-ol, S14




Prepared by General Procedure G using **S13** (240 mg, 0.496 mmol). The resulting crude material was purified by flash chromatography (petroleum ether / EtOAc (1:1)) to give **S14** as a colourless oil (178 mg, 0.482 mmol, 97%); $[\alpha]_D^{25} +164.1$ ($c = 0.7$, CHCl₃); IR (thin film, ν_{max} / cm⁻¹) 3410, 2950, 1598, 1351, 1254, 1163, 1067, 1090, 814, 700; ¹H NMR (400 MHz, CDCl₃) δ _H 7.77 (2H, d, $J = 8.2$ Hz, TsH), 7.31 (2H, d, $J = 8.2$ Hz, TsH), 7.23-7.21 (3H, m, PhH), 6.90 (2H, d, $J = 6.6$ Hz, PhH), 6.04 (1H, t, $J = 7.7$ Hz, H3), 5.38 (1H, d, $J = 2.7$ Hz, H9), 4.38 (1H, d, $J = 2.5$ Hz, H9), 4.09 (1H, dd, $J = 12.9$ and 8.5 Hz, H7), 3.96-3.90 (1H, m, H1), 3.88-3.82 (1H, m, H1), 3.29 (1H, dd, $J = 12.7$ and 11.0 Hz, H6), 3.09-3.00 (1H, m, H2), 2.90-2.84 (1H, m, H6), 2.80-2.71 (1H, m, H2), 2.47 (3H, s, TsCH₃); ¹³C NMR (101 MHz, CDCl₃) δ _C 148.06, 144.47, 140.36, 139.13, 135.72, 129.89, 129.70, 128.86, 128.76, 128.48, 128.35, 128.03, 127.69, 127.45, 127.32, 118.34, 106.66, 62.51, 57.01, 47.07, 33.08, 21.82, 21.75; HRMS (ES⁺) calc. for C₂₁H₂₃O₃NNaS [M+Na]⁺ 392.1290; found 392.1288.

(R,E)-3-(3-methyl-4-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrrol-2-yl)acrylaldehyde, 3b




Prepared by General Procedure **H** using **S14** (36 mg, 0.97 mmol). The resulting crude material was purified by flash chromatography (petroleum ether → petroleum ether / EtOAc (1:1)) to give **3b** as a light yellow oil (14.2 mg, 0.39 mmol, 40%); R_f 0.18 (petroleum ether / EtOAc (2:1)); $[\alpha]_D^{25} +32.6$ ($c = 1.0$, CHCl₃); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 2962, 2923, 1682, 1598, 1350, 1132, 1089, 1029, 732; **¹H NMR** (400 MHz, CDCl₃) δ_H 9.74 (1H, d, $J = 7.8$ Hz, H1), 7.58 (2H, d, $J = 8.3$ Hz, TsH), 7.51 (1H, d, $J = 16.1$ Hz, H3), 7.32 (2H, d, $J = 8.0$ Hz, PhH), 7.21-7.12 (3H, m, PhH), 6.65 (2H, d, $J = 8.1$ Hz, PhH), 6.42 (1H, dd, $J = 16.1$ and 7.8 Hz, H2), 4.46-3.95 (1H, m, H7), 3.68-3.40 (1H, m, H6), 2.49 (3H, s, TsCH₃), 1.58 (3H, s, H9); **¹³C NMR** (101 MHz, CDCl₃) δ_C 194.0, 144.5, 143.1, 140.7, 135.7, 134.3, 132.8, 132.7, 130.0, 129.0, 128.3, 127.8, 127.5, 56.8, 52.7, 21.8, 14.0; **HRMS** (ES⁺) calc. for C₂₁H₂₁O₃NNaS [M+Na]⁺ 390.1134; found 390.1135.

4e was synthesized according to the following scheme:




5-((*tert*-Butyldimethylsilyl)oxy)-1-phenylpent-1-yn-3-ol, S16




To a solution of phenylacetylene (2.46 mL 22.5 mmol, 1.5 equiv.) in THF (150 mL) at -78°C was added *n*-BuLi (2.4 M in hexanes, 8.1 mL, 19.5 mmol, 1.3 equiv.). The reaction mixture was stirred for 15 min. A solution of aldehyde **S15**⁷ (2.80 g, 15.0 mmol, 1.0 equiv.) in THF (21 mL) and added by cannula. The reaction was allowed to warm to rt, and was stirred for 16 h. The reaction was quenched via addition of NH₄Cl (50 mL, sat., aq.), and the aqueous layer was extracted with Et₂O. The combined organic extracts were dried (Na₂SO₄) and concentrated. Purification by flash chromatography (petroleum ether / EtOAc (9:1)) gave alcohol **S16** as a yellow oil (3.39 g, 11.7 mmol, 78%); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 3398, 2954, 2857, 1490, 1254, 1082, 833, 776; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 7.45-7.41 (2H, m, PhH), 7.32-7.29 (3H, m, PhH), 4.85 (1H, dd, *J* = 10.1 and 5.6 Hz, H3), 4.12 (1H, ddd, *J* = 10.3, 8.0 and 3.8 Hz, H5), 3.89 (1H, ddd, *J* = 10.2, 6.0 and 4.3 Hz, H5), 3.58 (1H, d, *J* = 5.4 Hz, OH), 2.14-2.06 (1H, m, H4), 1.97 (1H, dtd, *J* = 14.2, 6.2 and 3.8 Hz, H4), 0.92 (9H, s, SiC(CH₃)₃), 0.11 (3H, s, Si(CH₃)₂), 0.10 (3H, s, Si(CH₃)₂); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 131.6, 131.6, 128.1, 122.8, 89.6, 84.7, 61.9, 61.0, 38.8, 25.7, 18.1, -5.6; **HRMS** (ES⁺) calc. for C₁₇H₂₆O₂NaSi [M+Na]⁺ 313.1605; found 313.1598.

5-((*tert*-Butyldimethylsilyl)oxy)-1-phenylpent-1-yn-3-one, S17




Prepared by General Procedure I using **S16** (870 mg, 3.00 mmol, 1.0 equiv.). The resulting crude material was purified by flash chromatography (petroleum ether \rightarrow petroleum ether / EtOAc (9:1)) to give **S17** as a yellow oil (734 mg, 2.54 mmol, 85%); **IR** (thin film, $\nu_{\text{max}} / \text{cm}^{-1}$) 2954, 2857, 2200, 1668, 1490, 1280, 1089, 1032, 926, 833; **¹H NMR** (400 MHz, CDCl₃) δ_{H} 7.58-7.56 (2H, m, PhH), 7.48-7.43 (1H, m, PhH), 7.40-7.36 (2H, m, PhH), 4.05 (2H, t, *J* = 6.2 Hz, H5), 2.87 (2H, t, *J* = 6.2 Hz, H4), 0.88 (9H, s, SiC(CH₃)₃), 0.07 (6H, s, Si(CH₃)₂); **¹³C NMR** (101 MHz, CDCl₃) δ_{C} 186.3, 133.0, 130.7, 128.6, 120.0, 90.9, 87.9, 58.5, 48.5, 25.8, 18.2, -5.4; **HRMS** (ES⁺) calc. for C₁₇H₂₅O₂Si [M+H]⁺ 289.1629, found 289.1621.

(*S,E*)-5-((*tert*-butyldimethylsilyl)oxy)-1-phenylpent-1-en-3-ol, S18




To a solution of **S17** (576 mg, 2.00 mmol, 1.0 equiv.) in *i*-PrOH (20 mL) under Ar at rt was added dropwise a solution of RuCl(*p*-cymene)[(S,S)-Ts-DPEN] (63.6 mg, 0.10 mmol, 0.05 equiv.) in CH₂Cl₂ (2 mL). The reaction mixture was stirred for 1 h, and then concentrated. Purification by flash chromatography (petroleum ether / EtOAc (9:1)) gave (*S*)-propargyl alcohol **S16** (452 mg, 1.56 mmol, 78%); $[\alpha]_D^{25} -22.2$ (*c* = 0.9, CHCl₃); other data for this compound were identical to **S16** above.

Chiralpak IB (15% IPA in hexane, flow rate = 1.0 mL/min, 230 nm) *t*_Rmajor – 7.7 min, minor – 5.0 min.




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.046	MM T	0.1960	1.45970e4	1714.13611	49.3589
2	7.762	MM T	0.1869	1.49762e4	1335.23193	50.6411



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.048	MM T	0.1372	543.62360	66.04488	2.4739
2	7.691	MM T	0.2534	2.14306e4	1855.92432	97.5261

To a solution of (*S*)-**S16** (840 mg, 2.90 mmol, 1.0 equiv.) in Et₂O at 0 °C was added Red Al (65% wt solution in toluene, 1.3 mL, 4.35 mmol, 1.5 equiv.) dropwise, and the reaction was stirred for 2 h at rt. The reaction was quenched by addition of 1N HCl, and extracted with Et₂O. The combined organic phases were washed with NaHCO₃ (sat., aq.), dried (MgSO₄) and concentrated. The crude residue was purified by flash chromatography (petroleum ether / EtOAc (9:1)) to give **S18** as a light yellow oil (490 mg, 1.68 mmol, 58%); $[\alpha]_D^{25} -1.83$ (*c* = 1.0, CHCl₃); **IR** (thin film, ν_{max} / cm⁻¹) 3417, 2953, 2929, 1494, 1292, 1093, 965, 834 and 775; **¹H NMR** (400 MHz, CDCl₃) δ _H 7.30-7.27 (2H, m, PhH), 7.23-7.18 (2H, m, PhH), 7.16-7.11 (1H, m, PhH), 6.54 (1H, dd, *J* = 15.9 and 3.4 Hz, H2), 6.14 (1H, d, *J* = 15.9 Hz, H1), 4.45 (1H, br s, H3), 3.83 (1H, td, *J* = 10.1 and 5.1 Hz, H5), 3.79-3.72 (1H, m, H5), 3.45 (1H, br s, OH), 1.78-1.71 (2H, m, H2), 0.82 (9H, m, SiC(CH₃)₃), 0.00 (3H, s, Si(CH₃)₂), -0.01 (3H, s, Si(CH₃)₂); **¹³C NMR** (101 MHz, CDCl₃) δ _C 137.0, 132.1, 129.5, 128.5, 127.4, 126.4, 72.3, 62.0, 38.6, 25.9, 18.2, -5.5; **HRMS** (ES⁺) calc. for C₁₇H₂₈O₂NaSi [M+Na]⁺ 315.1761, found 315.1749.


(*S,E*)-5-((tert-Butyldimethylsilyl)oxy)-1-phenylpent-1-en-3-yl propionate, **S19**



Pyridine (49 mg, 0.625 mmol, 1.25 equiv.), propanoic anhydride (81 mg, 0.625 mmol, 1.25 equiv.) and DMAP (0.6 mg, 0.005 mmol, 0.01 equiv.) were added to a solution of **S18** (145 mg, 0.50 mmol, 1.0 equiv.) in Et₂O (20 mL) at rt. The reaction mixture was stirred for 2 h, then it was diluted with toluene (10 mL) and concentrated. Purification by flash chromatography (petroleum ether / EtOAc (19:1)) gave **S19** as a colourless oil (160 mg, 0.46 mmol, 93%); $[\alpha]_D^{25} -1.2$ (*c* = 1.0, CHCl₃); **IR** (thin film, ν_{max} / cm⁻¹) 2954, 2859,


1737, 1604, 1471, 1254, 1180, 1095, 963, 834; **¹H NMR** (400 MHz, CDCl₃) δ_H 7.33 (2H, d, *J* = 7.1 Hz, PhH), 7.26 (2H, t, *J* = 7.4 Hz, PhH), 7.20 (1H, m, PhH), 6.57 (1H, d, *J* = 15.9 Hz, H1), 6.11 (1H, dd, *J* = 15.9 and 7.3 Hz, H2), 5.53 (1H, dd, *J* = 13.6 and 6.8 Hz, H3), 3.65 (2H, t, *J* = 6.1 Hz, H5), 2.30 (2H, q, *J* = 7.6 Hz, H7), 1.98-1.71 (2H, m, H4), 1.11 (3H, t, *J* = 7.6 Hz, H8), 0.85 (9H, s, SiC(CH₃)₃), 0.00 (6H, s, Si(CH₃)₂); **¹³C NMR** (101 MHz, CDCl₃) δ_C 173.6, 136.4, 132.4, 128.6, 127.9, 127.7, 126.6, 71.7, 59.1, 37.6, 27.9, 25.9, 18.3, 9.2, -5.4; **HRMS** (ES⁺) calc. for C₂₀H₃₃O₃Si [M+H]⁺ 349.2193; found 349.2190.

(2*R*,3*R*,*E*)-7-((tert-Butyldimethylsilyl)oxy)-2-methyl-3-phenylhept-4-enoic acid, **S20**



A solution of **S19** (576 mg, 1.65 mmol, 1.0 equiv.) in toluene (16 mL) was added dropwise to a solution of LiHMDS (4.9 mL, 4.96 mmol, 3.0 equiv.) and Et₃N (6.9 mL, 4.96 mmol, 30 equiv.) in toluene (16 mL) at -78 °C. The reaction was stirred for 1 h at -78 °C, then it was allowed to warm to rt and stirred for 12 h. 1N NaOH was added to the reaction mixture, which was stirred for a further 1h and then extracted with ether. The aqueous layer was neutralized with 1N citric acid, then extracted with ether and concentrated to give acid **S20** as a colourless oil (430 mg, 1.23 mmol, 75%); [α]_D²⁵ +30.8 (*c* = 1.4, CHCl₃); **IR** (thin film, ν_{max} / cm⁻¹) 2954, 1820, 1713, 1462, 1288, 1150, 1092, 834, 755; **¹H NMR** (400 MHz, CDCl₃) δ_H 10.69 (1H, s, CO₂H), 7.26-7.20 (2H, m, PhH), 7.16 (3H, d, *J* = 7.3 Hz, PhH), 5.59-5.48 (2H, m, H4 and H5), 3.59 (2H, t, *J* = 6.6 Hz, H7), 3.44 (1H, t, *J* = 8.7 Hz, H3), 2.79-2.70 (1H, m, H2), 2.20 (2H, q, *J* = 6.2 Hz, H6), 1.19 (3H, d, *J* = 6.9 Hz, H8), 0.86 (9H, s, SiC(CH₃)₃), 0.01 (6H, s, Si(CH₃)₂); **¹³C NMR** (101 MHz, CDCl₃) δ_C 181.4, 142.5, 131.8, 129.5, 128.4, 127.6, 126.4, 62.8, 52.1, 45.0, 36.1, 25.9, 18.3, 15.5, -5.4; **HRMS** (ES⁺) calc. for C₂₀H₃₃O₃Si [M+H]⁺ 349.2199; found 349.2194.

N-((2*R*,3*S*,*E*)-7-((tert-Butyldimethylsilyl)oxy)-3-phenylhept-4-en-2-yl)-4-methylbenzenesulfonamide, **S21**




To a solution of carboxylic acid **S20** (170 mg, 0.48 mmol, 1.0 equiv.) in toluene (5 mL) were added Et₃N (0.25 mL, 1.79 mmol, 3.0 equiv.) and diphenylphosphoryl azide (DPPA) (0.25 mL, 1.16 mmol, 2.0 equiv.). The mixture was stirred at rt for 30 min, then stirred at 80 °C for 4 h. The reaction mixture was concentrated and re-dissolved in THF (5 mL). 4N LiOH (2.8 mL) was added, and the mixture was stirred for 4 h at rt, then it was diluted with water and extracted with EtOAc. The organic layer was dried (Na₂SO₄) and concentrated to give the crude amine as an oil, which was used without further purification.

To a stirred solution of the crude amine (assumed 0.48 mmol, 1.0 equiv.) and TsCl (91 mg, 0.48 mmol, 1.0 equiv.) in CH₂Cl₂ (5 mL) was added Et₃N (0.75 mL, 5.36 mmol) dropwise. The mixture was stirred for 2 h, then it was concentrated and purified by flash chromatography (petroleum ether / EtOAc (9:1)) to give **S21** (150 mg, 0.317 mmol, 65%) as a colorless oil; [α]_D²⁵ +13.0 (*c* = 0.8, CHCl₃); **IR** (thin film, ν_{max} / cm⁻¹) 3280, 2954, 2928, 1599, 1304, 1253, 1158, 1093, 835; **¹H NMR** (400 MHz, CDCl₃) δ_H 7.68 (2H, d, *J* = 8.2 Hz, TsH),


7.32–7.28 (3H, m, 2 x TsH and PhH), 7.23 (2H, d, J = 7.9 Hz, PhH), 7.05 (2H, d, J = 6.4 Hz, PhH), 5.67 (1H, dd, J = 15.2 and 9.4 Hz, H4), 5.55–5.46 (1H, m, H5), 4.42 (1H, d, J = 7.8 Hz, NHTs), 3.65 (2H, t, J = 6.5 Hz, H7), 3.58 (1H, dt, J = 13.2 and 6.6 Hz, H2), 3.22 (1H, dd, J = 9.3 and 6.3 Hz, H3), 2.47 (3H, s, TsCH₃), 2.26 (2H, q, J = 6.5 Hz, H6), 1.11 (3H, d, J = 6.6 Hz, H8), 0.91 (9H, s, SiC(CH₃)₃), 0.07 (3H, s, Si(CH₃)₂), 0.07 (3H, s, Si(CH₃)₂); ¹³C NMR (101 MHz, CDCl₃) δ _C 143.1, 140.6, 137.8, 131.6, 129.6, 129.2, 128.6, 127.8, 127.1, 126.8, 62.6, 54.4, 53.5, 36.3, 25.9, 21.5, 18.6, 18.3, –5.3; HRMS (ES⁺) calc. for C₂₆H₃₉O₃NNaSSi [M+Na]⁺ 496.2317; found 496.2308.

N-((2*R*,3*S*,*E*)-7-((tert-Butyldimethylsilyl)oxy)-3-phenylhept-4-en-2-yl)-4-methyl-N-(prop-1-yn-1-yl)benzenesulfonamide, 5g



Prepared by General Procedures D and E using sulfonamide **S21** (230 mg, 0.49 mmol). The resulting crude material was purified by flash chromatography (petroleum ether / EtOAc (95:5)) to give **5g** as a colourless oil (217 mg, 0.42 mmol, 87%); $[\alpha]_D^{25}$ +28.3 (c = 0.7, CHCl₃); IR (thin film, ν_{max} / cm^{–1}) 2955, 2855, 1714, 1551, 1479, 1349, 1162, 1089, 815, 756; ¹H NMR (400 MHz, CDCl₃) δ _H 7.31 (2H, d, J = 8.2 Hz, TsH), 7.22–7.17 (5H, m, TsH and PhH), 7.11 (2H, d, J = 8.1 Hz, PhH), 5.63 (1H, dd, J = 15.2 and 9.1 Hz, H4), 5.55–5.48 (1H, m, H5), 4.31 (1H, dq, J = 10.4 and 6.5 Hz, H2), 3.59 (2H, t, J = 6.7 Hz, H7), 3.38 (1H, t, J = 9.7 Hz, H3), 2.38 (3H, s, Me), 2.21 (2H, q, J = 6.6 Hz, H6), 1.93 (3H, s, TsCH₃), 1.22 (3H, d, J = 6.5 Hz, H8), 0.86 (9H, s, SiC(CH₃)₃), 0.00 (3H, s, Si(CH₃)₂), 0.00 (3H, s, Si(CH₃)₂); ¹³C NMR (101 MHz, CDCl₃) δ _C 143.6, 142.0, 135.6, 131.6, 129.9, 129.2, 128.4, 127.8, 127.4, 126.4, 68.8, 68.2, 62.7, 59.2, 54.3, 36.2, 25.8, 21.5, 18.3, 17.6, 3.5, –5.4; HRMS (ES⁺) calc. for C₂₉H₄₁O₃NNaSSi [M+Na]⁺ 534.2474; found 534.2464.


(3*R*,4*S*,5*R*,*Z*)-3-((*E*)-3-((tert-butyldimethylsilyl)oxy)prop-1-en-1-yl)-2-ethylidene-5-methyl-4-phenyl-1-tosylpyrrolidine, S22



Prepared by General Procedure F using ynamide **5g** (100 mg, 0.195 mmol). The crude material was purified by column chromatography (petroleum ether / EtOAc (95:5)) to give **S22** as colorless oil (95 mg, 0.185 mmol, 95%); $[\alpha]_D^{25}$ +68.2 (c = 0.7, CHCl₃); IR (thin film, ν_{max} / cm^{–1}) 2954, 2856, 1471, 1354, 1353, 1197, 1072, 835, 776; ¹H NMR (500 MHz, CDCl₃) δ _H 7.81 (2H, d, J = 8.3 Hz, TsH), 7.35 (2H, d, J = 8.0 Hz, TsH), 7.24–7.20 (2H, m, PhH), 7.16 (1H, t, J = 6.7 Hz, PhH), 6.94 (2H, d, J = 7.3 Hz, PhH), 5.49 (1H, dt, J = 15.1 and 5.3 Hz, H2), 5.39 (1H, qd, J = 7.1 and 1.6 Hz, H9), 4.98 (1H, dd, J = 15.1 and 8.8 Hz, H3), 4.28 (1H, d, J = 6.8 Hz, H6), 3.99 (2H, dd, J = 5.2 and 1.5 Hz, H1), 3.53 (1H, t, J = 10.0 Hz, H4), 2.44 (3H, s, TsCH₃), 2.31 (1H, dt, J = 13.1 and 9.8 Hz, H5), 1.98 (3H, dd, J = 7.2 and 1.9 Hz, H10), 0.86 (3H, d, J = 6.8 Hz, H11), 0.84 (9H, s, SiC(CH₃)₃), –0.02 (3H, s, Si(CH₃)₂), –0.04 (3H, s, Si(CH₃)₂); ¹³C NMR (126 MHz, CDCl₃) δ _C 143.9, 138.5,


137.1, 136.4, 131.7, 130.6, 129.6, 128.4, 128.2, 127.8, 126.8, 118.4, 63.4, 61.9, 50.6, 48.3, 25.9, 21.6, 18.3, 15.9, 15.9, -5.2; **HRMS** (ES⁺) calc. for C₂₉H₄₁O₃NNaSSi [M+Na]⁺ 534.2474; found 534.2468.

(E)-3-((3*R*,4*S*,5*R*,*Z*)-2-ethylidene-5-methyl-4-phenyl-1-tosylpyrrolidin-3-yl)prop-2-en-1-ol, S23



Prepared by General Procedure **G** using **S22** (80 mg, 0.156 mmol). The resulting crude material was purified by flash chromatography (petroleum ether / EtOAc (1:1)) to give **S23** as a colourless oil (58 mg, 0.146 mmol, 93%); $[\alpha]_D^{25} +145.7$ (*c* = 0.7, CHCl₃); **IR** (thin film, ν_{max} / cm⁻¹) 3378, 3028, 2919, 1677, 1452, 1304, 1164, 1053, 977, 814; **¹H NMR** (500 MHz, CDCl₃) δ_H 7.82 (2H, d, *J* = 8.3 Hz, TsH), 7.36 (2H, d, *J* = 8.0 Hz, TsH), 7.27-7.21 (2H, m, PhH), 7.18 (1H, t, *J* = 6.2 Hz, PhH), 6.97 (2H, d, *J* = 7.3 Hz, PhH), 5.59 (1H, dt, *J* = 11.3 and 5.5 Hz, H2), 5.46-5.35 (1H, m, H9), 5.01 (1H, dd, *J* = 14.6 and 9.3 Hz, H3), 4.31 (1H, quint, *J* = 6.9 Hz, H6), 3.97 (2H, d, *J* = 4.5 Hz, H1), 3.55 (1H, t, *J* = 9.6 Hz, H4), 2.48-2.42 (1H, m, H5), 2.45 (3H, s, TsCH₃), 1.97 (3H, dd, *J* = 7.1 and 1.8 Hz, H10), 0.85 (3H, d, *J* = 6.8 Hz, H11); **¹³C NMR** (126 MHz, CDCl₃) δ_C 144.1, 138.4, 137.0, 136.4, 132.4, 131.0, 129.6, 128.5, 128.2, 127.9, 126.9, 118.8, 63.2, 62.0, 50.7, 48.2, 21.6, 15.9, 15.8; **HRMS** (ES⁺) calc. for C₂₃H₂₇O₃NNaS [M+Na]⁺ 420.1609; found 420.1599.


(E)-3-((3*R*,4*S*,5*R*,*Z*)-2-ethylidene-5-methyl-4-phenyl-1-tosylpyrrolidin-3-yl)acrylaldehyde, 4e



Prepared by General Procedure **I** using **S23** (46 mg, 0.115 mmol, 1.0 equiv.). The resulting crude material was purified by flash chromatography (petroleum ether → petroleum ether / EtOAc (1:1)) to give **4e** as a light yellow oil (30 mg, 0.076 mmol, 66%); $[\alpha]_D^{25} +136.8$ (*c* = 0.7, CHCl₃); **IR** (thin film, ν_{max} / cm⁻¹) 3030, 2919, 1686, 1632, 1453, 1165, 1053, 978, 815; **¹H NMR** (400 MHz, CDCl₃) δ_H 9.22 (1H, d, *J* = 7.7 Hz, H1), 7.76 (2H, d, *J* = 8.3 Hz, TsH), 7.30 (2H, d, *J* = 8.0 Hz, TsH), 7.22-7.12 (3H, m, PhH), 6.92 (2H, d, *J* = 8.5 Hz, PhH), 6.01 (1H, dd, *J* = 15.5 and 8.5 Hz, H3), 5.86 (1H, dd, *J* = 15.8 and 7.7 Hz, H2), 5.36 (1H, qd, *J* = 7.0 and 1.4 Hz, H9), 4.33 (1H, qt, *J* = 6.8 Hz, H6), 3.75 (1H, t, *J* = 9.5 Hz, H4), 2.63 (1H, dd, *J* = 10.6 and 7.1 Hz, H5), 2.38 (3H, s, TsCH₃), 1.92 (3H, dd, *J* = 7.1 and 1.8 Hz, H10), 0.82 (3H, d, *J* = 6.8 Hz, H11); **¹³C NMR** (101 MHz, CDCl₃) δ_C 193.1, 156.4, 144.5, 136.6, 136.1, 135.9, 132.7, 129.8, 128.7, 127.9, 127.4, 121.1, 62.2, 50.9, 48.7, 21.6, 16.0, 15.9; **HRMS** (ES⁺) calc. for C₂₃H₂₅O₃NNaS [M+Na]⁺ 418.1452; found 418.1436.


1.3.6 Double stereodifferentiating cycloaddition reactions of dienals **3b and **4e****

2-((3*R*,5*S*,6*S*,7*R*)-6-nitro-3,5-diphenyl-1-tosyl-2,3,4,5,6,7-hexahydro-1*H*-indol-7-yl)acetaldehyde, **19a**




Prepared by General Procedure **J** using catalyst (*S*)-**10** (1.9 μ L, 0.006 mmol, 0.2 equiv.), **3b** (11 mg, 0.030 mmol, 1.0 equiv.) and trans- β -nitrostyrene **13a** (13.4 mg, 0.09 mmol, 3.0 equiv.) under Ar. Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave cycloadduct **19a** as a colourless oil (9.0 mg, 0.017 mmol, 58%, 8:1 dr); $[\alpha]_D^{25} +9.35$ ($c = 0.6$, CHCl₃); **IR** (thin film, ν_{max} / cm⁻¹) 2926, 1716, 1651, 1553, 1348, 1324, 1160; **¹H NMR** (500 MHz, CDCl₃) δ _H 9.77 (1H, s), 7.66 (2H, d, $J = 8.3$ Hz, TsH), 7.34 (2H, d, $J = 8.0$ Hz, TsH), 7.30-7.23 (3H, m, PhH), 7.18 (2H, d, $J = 7.0$ Hz, PhH), 7.07 (1H, t, $J = 7.4$ Hz, PhH), 6.96 (2H, t, $J = 6.8$ Hz, PhH), 6.24 (2H, d, $J = 7.1$ Hz, PhH), 5.14 (1H, dd, $J = 10.2$ and 7.3 Hz, H6), 4.23 (1H, dd, $J = 12.3$ and 11.7 Hz, H2), 3.98 (1H, br s, H7), 3.78 (1H, br d, $J = 10.4$ Hz, H3), 3.51 (1H, dd, $J = 12.4$ and 4.8 Hz, H2), 3.45 (1H, td, $J = 9.9$ and 5.1 Hz, H5), 3.35 (1H, dd, $J = 19.4$ and 6.1 Hz, H8), 3.04 (1H, dd, $J = 19.4$ and 2.9 Hz, H8), 2.53 (3H, s, TsCH₃), 2.42 (1H, dddd, $J = 17.9$, 9.6, 3.0 and 1.8 Hz, H4), 2.04 (1H, dd, $J = 17.9$ and 4.9 Hz, H4); **¹³C NMR** (126 MHz, CDCl₃) δ _C 199.8, 144.7, 140.9, 138.6, 134.8, 132.1, 130.3, 129.1, 128.7, 128.6, 128.2, 127.7, 127.5, 127.1, 126.8, 92.5, 57.4, 48.9, 44.6, 43.6, 36.4, 28.9, 21.8; **HRMS** (ES⁺) calc. for C₂₉H₂₈O₅N₂NaS [M+Na]⁺ 539.1611; found 539.1610.

Assignment of stereochemistry: The stereochemistry of cycloadduct **19a** was assigned by ¹H NMR nOe experiments (2D NOESY). On the alpha face (as depicted below), enhancements were seen between H7 and H5, and between H5 and H4 α , indicating these protons to be on the same face. On the beta face, enhancements was seen between H3 and H4 β , between H4 β and H6, and between H6 and H8 (sidechain), indicating these protons to be on the opposite face. This analysis is consistent with a top face attack of nitrostyrene, with the nitro group oriented *exo* and the phenyl ring oriented *endo*. This is consistent with the acyclic trienamine catalysis reported by Chen.⁸ As such, the facial and diastereoselectivity of the reaction is under catalyst stereocontrol.




2-((3*R*,5*R*,6*R*,7*S*)-6-nitro-3,5-diphenyl-1-tosyl-2,3,4,5,6,7-hexahydro-1*H*-indol-7-yl)acetaldehyde, 19b




Prepared by General Procedure **J** using catalyst (*R*)-**10** (i.e. *ent*-**10**) (1.9 μ L, 0.006 mmol, 0.2 equiv.), **3b** (11 mg, 0.030 mmol, 1.0 equiv.) and trans- β -nitrostyrene **13a** (13.4 mg, 0.09 mmol, 3.0 equiv.) under Ar. Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave cycloadduct **19b** as a colourless oil (8.2 mg, 0.016 mmol, 53%, 20:1 dr); $[\alpha]_D^{25} -46.0$ ($c = 0.5$, CHCl₃); **IR** (thin film, ν_{max} / cm⁻¹) 2961, 2923, 1723, 1598, 1379, 1100, 1088, 728; **¹H NMR** (500 MHz, CDCl₃) δ _H 9.77 (1H, s, H9), 7.76 (2H, d, J = 8.3 Hz, TsH), 7.44 (2H, d, J = 8.0 Hz, TsH), 7.32 (2H, t, J = 7.4 Hz, PhH), 7.28-7.25 (3H, m), 7.22 (1H, d, J = 7.2 Hz, PhH), 7.12 (2H, d, J = 7.0 Hz, PhH), 7.07 (2H, d, J = 7.0 Hz, PhH), 5.19 (1H, dd, J = 10.8 and 5.4 Hz, H6), 4.47-4.42 (1H, m, H7), 4.12 (1H, dd, J = 12.0 and 9.7 Hz, H2), 3.83 (1H, dd, J = 12.0 and 7.7 Hz, H2), 3.54 (1H, br t, J = 8.5 Hz, H3), 3.37 (1H, td, J = 9.7 and 6.5 Hz, H5), 3.27 (1H, dd, J = 18.5 and 2.2 Hz, H8), 3.09 (1H, dd, J = 18.3 and 8.3 Hz, H8), 2.53 (3H, s, TsCH₃), 2.15 (1H, dd, J = 18.2 and 6.5 Hz, H4), 2.00 (1H, ddt, J = 18.3, 9.4 and 1.8 Hz, H4); **¹³C NMR** (126 MHz, CDCl₃) δ _C 198.1, 144.8, 140.8, 139.2, 135.3, 133.9, 130.3, 129.3, 129.1, 128.0, 127.9, 127.8, 127.6, 127.4, 127.1, 89.0, 58.6, 49.0, 43.4, 39.9, 32.2, 29.8, 21.9; **HRMS** (ES⁺) calc. for C₂₉H₂₈O₅N₂NaS [M+Na]⁺ 539.1611; found 539.1610.

Assignment of stereochemistry: The stereochemistry of cycloadduct **19b** was assigned through ¹H NMR nOe experiments (2D NOESY). On the alpha face (as depicted below), enhancements were seen between H5 and H4 α , and between H5 and H8 (sidechain), indicating these protons to be on the same face. On the beta face, enhancements was seen between H3 and H4 β , between H4 β and H6, and between H6 and H7, indicating these protons to be on the opposite face. This analysis is consistent with a bottom face attack of nitrostyrene, with the nitro group oriented *endo* and the phenyl ring oriented *exo*. This reverses the diastereoselectivity of trienamine catalysis observed by Chen,⁸ and likely arises from an avoidance of steric interactions between the C3-phenyl group, and the phenyl ring of nitrostyrene, in the Diels-Alder transition state. As such, the facial selectivity of the reaction is under catalyst stereocontrol, but the diastereoselectivity is under substrate control.




(3*R*,3'*S*,5*S*,7*R*)-1'-*tert*-butyl 5-ethyl 2'-oxo-7-(2-oxoethyl)-3-phenyl-1-tosyl-1,2,3,4,5,7-hexahydrospiro[indole-6,3'-indoline]-1',5-dicarboxylate, 11e




Prepared by General Procedure **K** using catalyst (*S*)-**10** (1.9 μ L, 0.011 mmol, 0.2 equiv.), **3b** (11 mg, 0.030 mmol, 1.0 equiv.) and olefinic oxindole **9a** (28 mg, 0.090 mmol, 3.0 equiv.) under Ar. Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave **11e** as a colourless oil (13 mg, 0.019 mmol, 63%, 7:1 dr); $[\alpha]_D^{25} -67.8$ ($c = 0.8$, CHCl₃); **IR** (thin film, ν_{max} / cm⁻¹) 2930, 1787, 1756, 1722, 1597, 1484, 1278, 1155, 771; **¹H NMR** (500 MHz, CDCl₃) δ _H 9.74 (1H, s, H9), 8.02 (1H, d, *J* = 8.1 Hz, oxindole H7'), 7.37 (1H, t, *J* = 8.8 Hz, oxindole H6'), 7.33 (2H, d, *J* = 8.3 Hz, TsH), 7.20 (1H, t, *J* = 7.9 Hz, PhH), 7.15-7.11 (4H, m, TsH and PhH), 6.81 (1H, t, *J* = 7.1 Hz, oxindole H5'), 6.58 (1H, d, *J* = 6.9 Hz, oxindole H4'), 6.51 (2H, d, *J* = 8.3 Hz, PhH), 4.36 (1H, t, *J* = 11.6 Hz, H2), 3.89-3.81 (3H, m, OCH₂CH₃, H3 and H7), 3.77 (1H, dq, *J* = 10.9 and 7.1 Hz, OCH₂CH₃), 3.58 (1H, dd, *J* = 11.9 and 6.3 Hz, H2), 3.35-3.27 (2H, m, H5 and H8), 3.15 (1H, d, *J* = 17.8 Hz, H8), 2.52 (3H, TsCH₃), 2.58-2.48 (1H, m, H4), 2.03 (1H, dd, *J* = 18.4 and 11.8 Hz, H4), 1.65 (9H, s, C(CH₃)₃), 0.95 (3H, t, *J* = 7.1 Hz, OCH₂CH₃); **¹³C NMR** (126 MHz, CDCl₃) δ _C 198.1, 176.5, 171.3, 149.2, 144.1, 141.0, 140.0, 136.2, 133.1, 130.8, 130.2, 128.8, 128.4, 128.4, 127.6, 127.3, 123.6, 123.4, 122.5, 115.5, 84.2, 61.3, 56.8, 50.1, 49.9, 43.8, 41.3, 37.5, 28.2, 24.5, 21.8, 13.7; **HRMS** (ES⁺) calc. for C₃₈H₄₀O₈N₂NaS [M+Na]⁺ 707.2397; found 707.2391.

Assignment of stereochemistry: The stereochemistry of cycloadduct **11e** was assigned through ¹H NMR nOe experiments (2D NOESY). Several key protons are overlapping, but assignment can be made on the following basis: On the alpha face (as depicted below), a key enhancement was seen between oxindole H4' and H4 α , indicating these protons to be on the same face. H4 α did not show enhancements to any aliphatic protons aside from H4 β . On the beta face, enhancements were seen between H4 β and the overlapped H3/H7 peak (this must be an enhancement with H3 based on other compounds), and between H4 β and H5, indicating these protons all to be on the opposite face. This analysis is consistent with a top face attack of the oxindole, with the oxindole carbonyl oriented *endo* and the ester group oriented *exo*. These observations are consistent with the model proposed by Jørgensen and Chen for acyclic trienamine reactions with oxindole alkene dienophiles.⁸




(3*R*,3'*R*,5*R*,7*S*)-1'-*tert*-butyl 5-ethyl 2'-oxo-7-(2-oxoethyl)-3-phenyl-1-tosyl-1,2,3,4,5,7-hexahydrospiro[indole-6,3'-indoline]-1',5-dicarboxylate, 11f




Prepared by General Procedure K using catalyst (*R*)-10 (i.e. *ent*-10) (1.9 μ L, 0.011 mmol, 0.2 equiv.), 3b (11 mg, 0.030 mmol, 1.0 equiv.) and olefinic oxindole 9a (28 mg, 0.090 mmol, 3.0 equiv.) under Ar. Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave cycloadducts 11f as a light yellow oil (11 mg, 0.016 mmol, 53%, 1:1 dr); $[\alpha]_D^{25} -6.2$ ($c = 1.0$, CHCl₃); IR (thin film, ν_{\max} / cm⁻¹) 2985, 2929, 1792, 1759, 1723, 1479, 1395, 1350, 1164, 1108, 775; ¹H NMR (500 MHz, CDCl₃) δ _H 9.74 (1H, s, H9A), 9.38 (1H, s, H9B), 7.98 (1H, d, $J = 8.1$ Hz, PhH), 7.93 (1H, d, $J = 7.9$ Hz, PhH), 7.84 (2H, d, $J = 8.3$ Hz, TsH), 7.44 (2H, d, $J = 8.0$ Hz, TsH), 7.41-7.29 (10H, m, TsH and PhH), 7.19 (2H, d, $J = 6.9$ Hz, PhH), 7.10 (2H, d, $J = 7.1$ Hz, PhH), 7.05 (3H, d, $J = 8.0$ Hz, PhH), 6.89 (1H, d, $J = 7.5$ Hz, PhH), 6.76 (1H, t, $J = 7.6$ Hz, oxindole H4'B), 6.63 (1H, d, $J = 7.6$ Hz, oxindole H4'A), 4.28 (1H, dd, $J = 13.4$ and 8.3 Hz, H2), 4.04-3.91 (3H, m, H2), 3.87-3.72 (6H, m, OCH₂CH₃ and H3), 3.38-3.24 (1H, m, H7 and H8A), 3.25-3.12 (3H, m, H5, H7, and H8A), 2.76 (1H, dt, $J = 17.7$ and 2.3 Hz, H8B), 2.53 (3H, s, TsCH₃), 2.53-2.50 (1H, m, H8B), 2.50-2.46 (1H, m, H4A/B), 2.42 (3H, s), 2.45-2.37 (1H, m, H4), 2.35-2.20 (2H, m, H4A and H4B), 2.19-2.11 (1H, m, H4A/B), 1.67 (9H, s, C(CH₃)₃), 1.65 (9H, s, C(CH₃)₃), 0.96-0.90 (6H, m, OCH₂CH₃); ¹³C NMR (126 MHz, CDCl₃) δ _C 199.2, 198.1, 177.3, 176.3, 171.3, 170.2, 149.2, 149.1, 145.0, 143.9, 141.9, 141.0, 139.9, 139.2, 137.3, 136.9, 133.5, 133.2, 132.1, 130.6, 130.1, 130.0, 129.7, 129.4, 129.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.4, 126.1, 124.6, 124.2, 123.9, 123.6, 123.0, 115.7, 115.34, 84.7, 84.3, 61.5, 61.2, 58.6, 57.7, 52.8, 50.7, 50.0, 48.5, 46.5, 43.9, 41.9, 41.5, 41.0, 37.0, 28.3, 28.2, 26.0, 23.9, 23.7, 21.9, 21.8, 13.7, 13.6; HRMS (ES⁺) calc. for C₃₈H₄₀O₈N₂NaS [M+Na]⁺ 707.2397; found 707.2391.

Assignment of stereochemistry: The two diastereomers produced in this reaction are different to those prepared in the matched reaction (to give 11e) assigned above. This supports an opposite (catalyst controlled) facial selectivity, and a 1:1 mixture of *endo* and *exo* adducts, which would be consistent with a steric effect imposed by the C3-phenyl affecting the mismatched catalyst-imposed diastereoselectivity. Additional evidence for the stereochemistry of these diastereomers is as follows: For isomer 11f_A, an enhancement was seen between the oxindole H4' and H4(β), but no enhancement was seen from oxindole H4' to H8. For isomer 11f_B, enhancements were seen between oxindole H4'B and H4(α), as well as between oxindole H4'B and H8, implying these protons to be on the same face.




(2*R*,3*R*,3*'R*,4*R*,6*R*,7*R*)-1'-*tert*-Butyl 6-ethyl 2,7-dimethyl-2'-oxo-4-(2-oxoethyl)-3-phenyl-1-tosyl-1,2,3,4,6,7-hexahydrospiro[indole-5,3'-indoline]-1',6-dicarboxylate, 12h




Prepared by General Procedure **K** using catalyst (*R*)-**10** (i.e. **ent-12a**) (3.56 μ L, 0.011 mmol, 0.2 equiv.), **4e** (21 mg, 0.055 mmol, 1.0 equiv.) and olefinic oxindole **9a** (52 mg, 0.165 mmol, 3.0 equiv.) under Ar. Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave cycloadduct **12h** as a colourless oil (24 mg, 0.033 mmol, 60% yield, 20:1 dr); $[\alpha]_D^{25} -10.38$ ($c = 1.1$, CHCl₃); **IR** (thin film, ν_{max} / cm⁻¹) 2980, 2931, 1789, 1758, 1726, 1291, 1252, 1150; **¹H NMR** (400 MHz, CDCl₃) δ _H 9.50 (s, 1H, H10), 7.85-7.81 (3H, m, TsH and PhH), 7.38-7.26 (5H, m, TsH and PhH), 7.11-7.04 (2H, m, PhH), 6.95 (2H, t, $J = 7.6$ Hz, PhH), 6.58 (2H, d, $J = 7.2$ Hz, PhH), 4.54 (1H, dq, $J = 13.9$ and 6.9 Hz, H2), 3.91-3.80 (4H, m, OCH₂CH₃, H7 and H3), 3.22 (1H, d, $J = 7.3$ Hz, H6), 3.20 (1H, dd, $J = 16.6$ and 7.4 Hz, H9), 2.78 (1H, dd, $J = 7.3$ and 4.9 Hz, H4), 2.47 (3H, s, TsCH₃), 2.38 (1H, ddd, $J = 17.5$, 4.8 and 1.5 Hz, H9), 1.59 (9H, s, *t*-Bu), 1.51 (1H, d, $J = 6.5$ Hz, H8), 1.09 (1H, d, $J = 6.9$ Hz, H12), 0.91 (1H, t, $J = 7.1$ Hz, OCH₂CH₃); **¹³C NMR** (126 MHz, CDCl₃) δ _C 199.4, 176.6, 171.0, 149.1, 143.7, 142.9, 139.5, 139.3, 135.1, 130.4, 130.0, 129.7, 129.0, 128.3, 127.4, 127.0, 124.6, 123.6, 122.3, 115.1, 84.4, 64.7, 61.4, 52.8, 52.0, 51.3, 44.9, 36.3, 30.5, 28.2, 23.7, 21.7, 17.2, 13.6; **HRMS** (ES⁺) calc. for C₄₀H₄₄O₈N₂NaS [M+Na]⁺ 735.2716; found 735.2711.

Assignment of stereochemistry: The stereochemistry of cycloadduct **12h** was assigned through **¹H NMR** nOe experiments (1D nOe / 2D NOESY). On the beta face (as depicted below), an enhancement was seen between H6 and H8 (side chain methyl), indicating these groups to be on the same face; on the alpha face, an enhancement was seen between H4 and oxindole H4', indicating this arene to be positioned on the top face of the molecule and oriented into / over the indoline ring system.




(2*R*,3*R*,3'S,4*S*,6*S*,7*S*)-1'-*tert*-Butyl 6-ethyl 2,7-dimethyl-2'-oxo-4-(2-oxoethyl)-3-phenyl-1-tosyl-1,2,3,4,6,7-hexahydrospiro[indole-5,3'-indoline]-1',6-dicarboxylate, 12i



Prepared by General Procedure K using catalyst (*S*)-10 (1.6 μ L, 0.005 mmol, 0.2 equiv.), 4e (10 mg, 0.025 mmol, 1.0 equiv.) and olefinic oxindole 9a (23.7 mg, 0.075 mmol, 3.0 equiv.) under Ar. Purification via flash chromatography (petroleum ether / EtOAc (2:1)) gave cycloadduct 12i as a colourless oil (8 mg, 0.011 mmol, 45% yield, 7:1 dr); $[\alpha]_D^{25} -117.6$ ($c = 0.6$, CHCl₃); IR (thin film, ν_{max} / cm⁻¹); 2980, 2931, 1789, 1758, 1726, 1291, 1252, 1150; ¹H NMR (400 MHz, CDCl₃) δ _H 9.12 (1H, s, H10), 7.98 (2H, d, $J = 8.0$ Hz, TsH), 7.78 (1H, d, $J = 7.9$ Hz, PhH), 7.42 (2H, d, $J = 8.0$ Hz, TsH), 7.27-7.22 (5H, m, PhH), 7.20-7.14 (1H, m, PhH), 7.03 (2H, dd, $J = 7.6$ and 1.7 Hz, PhH), 6.41 (1H, td, $J = 7.6$ and 0.9 Hz, PhH), 6.31 (1H, d, $J = 7.6$ Hz, PhH), 4.39-4.33 (1H, m, H2), 3.98-3.93 (1H, m, H7), 3.86-3.78 (2H, m, OCH₂CH₃), 3.48 (1H, dd, $J = 9.5$ and 2.3 Hz, H3), 3.26 (1H, d, $J = 6.0$ Hz, H6), 3.00 - 2.91 (2H, m, H9 and H4), 2.53 (3H, s, TsCH₃), 1.67-1.60 (4H, m, H9 and H12), 1.56 (9H, s), 1.27 (3H, d, $J = 6.6$ Hz, H8), 0.86 (3H, t, $J = 7.1$ Hz, OCH₂CH₃); ¹³C NMR (126 MHz, CDCl₃) δ _C 198.2, 176.6, 171.0, 148.9, 144.3, 143.7, 139.1, 137.8, 135.3, 130.7, 130.1, 129.5, 128.6, 128.5, 128.2, 127.8, 123.5, 122.9, 121.9, 114.7, 84.1, 62.4, 61.2, 55.5, 52.0, 51.2, 44.0, 37.5, 29.1, 27.9, 24.2, 21.7, 18.3, 13.3; HRMS (ES⁺) calc. for C₄₀H₄₄O₈N₂NaS [M+Na]⁺ 735.2710; found 735.2709.

Assignment of stereochemistry: The stereochemistry of cycloadduct 12i was assigned through ¹H NMR nOe experiments (1D nOe / 2D NOESY). On the alpha face (as depicted below), a strong enhancement was seen between H6 and H8 (side chain methyl), indicating these groups to be on the same face; on the beta face, a strong enhancement was seen between H4 and oxindole H4', and also between H2 and H3, and H2 and oxindole H4', indicating this arene to be positioned on the top face of the molecule and oriented into / over the indoline ring system.



Notably, the minor diastereomers produced in the above two reactions were also different – the matched and mismatched cycloadditions thus giving two different sets of diastereoisomers, each corresponding to endo and exo isomers from the opposite sense of facial selectivity – i.e. the facial selectivity of cycloaddition in each case is very high, as observed for the equivalent oxindole cycloadditions with 3b.

2. REFERENCES


1. X. Zhang, Y. Zhang, J. Huang, R. P. Hsung, K. C. M. Kurtz, J. Oppenheimer, M. E. Petersen, I. K. Sagamanova, L. Shen and M. R. Tracey, *J. Org. Chem.*, 2006, **71**, 4170-4177.
2. S. J. Mansfield, C. D. Campbell, M. W. Jones and E. A. Anderson, *Chem. Commun.*, 2015, **51**, 3316-3319.
3. B. M. Trost, G. J. Tanoury, M. Lautens, C. Chan and D. T. Macpherson, *J. Am. Chem. Soc.*, 1994, **116**, 4255-4267.
4. P. R. Walker, C. D. Campbell, A. Suleman, G. Carr and E. A. Anderson, *Angew. Chem. Int. Ed.*, 2013, **52**, 9139-9143.
5. J. F. Teichert, S. Zhang, A. W. v. Zijl, J. W. Slaa, A. J. Minnaard and B. L. Feringa, *Org. Lett.*, 2010, **12**, 4658-4660.
6. C. L. Joe, T. P. Blaisdell, A. F. Geoghan and K. L. Tan, *J. Am. Chem. Soc.*, 2014, **136**, 8556-8559.
7. M. S. Mortensen, J. M. Osbourn and G. A. O'Doherty, *Org. Lett.*, 2007, **9**, 3105-3108.
8. Z.-J. Jia, Q. Zhou, Q.-Q. Zhou, P.-Q. Chen and Y.-C. Chen, *Angew. Chem. Int. Ed.*, 2011, **50**, 8638-8641.

3.NMR SPECTRA


3.1 Intermediates in the synthesis of dienal 3a

Methyl but-3-en-1-yl(tosyl)carbamate, S1

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




N-(But-3-en-1-yl)-N-(4-((tert-butyldimethylsilyl)oxy)but-1-yn-1-yl)-4-methylbenzenesulfonamide, 5a

¹H NMR (400 MHz, CDCl₃)





¹³C NMR (101 MHz, CDCl₃)




(Z)-2-(3-((*tert*-Butyldimethylsilyl)oxy)propylidene)-3-methylene-1-tosylpyrrolidine, S3

¹H NMR (400 MHz, CDCl₃)




(Z)-3-(3-Methylene-1-tosylpyrrolidin-2-ylidene)propan-1-ol, S4

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




Note: EtOAc contamination.

(E)-3-(3-Methyl-1-tosyl-4,5-dihydro-1*H*-pyrrol-2-yl)acrylaldehyde, 3a

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




3.2 Cycloaddition products of dienal **3a**



(*3'S,5S,7R*)-1'-*tert*-Butyl 5-ethyl 2'-oxo-7-(2-oxoethyl)-1-tosyl-1,2,3,4,5,7-hexahydrospiro[indole-6,3'-indoline]-1',5-dicarboxylate, **11a**

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)






(3'S,5S,7R)-1'-*tert*-Butyl 5-ethyl 5'-chloro-2'-oxo-7-(2-oxoethyl)-1-tosyl-1,2,3,4,5,7-hexahydrospiro[indole-6,3'-indoline]-1',5-dicarboxylate, 11b

¹H NMR (500 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




(*3'S,5S,7R*)-1'-*tert*-Butyl 5-ethyl 5'-methoxy-2'-oxo-7-(2-oxoethyl)-1-tosyl-1,2,3,4,5,7-hexahydrospiro[indole-6,3'-indoline]-1',5-dicarboxylate, 11c

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(3'S,5S,7R)-di-*tert*-Butyl 2'-oxo-7-(2-oxoethyl)-1-tosyl-1,2,3,4,5,7-hexahydrospiro[indole-6,3'-indoline]-1',5-dicarboxylate, 11d

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-Ethyl 4-((5*S*,6*S*,7*R*)-5-phenyl-6-nitro-1-tosyl-2,3,4,5,6,7-hexahydro-1*H*-indol-7-yl)but-2-enoate, 14a

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-Ethyl 4-((5S,6S,7R)-5-(4-chlorophenyl)-6-nitro-1-tosyl-2,3,4,5,6,7-hexahydro-1H-indol-7-yl)but-2-enoate, 14b

Note: a small amount of the Z-alkene ($E:Z = 20:1$) is observed ($J = 11.6$ Hz), but no diastereomer from the cycloaddition could be detected.

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-Ethyl 4-((5S,6S,7R)-5-(4-bromophenyl)-6-nitro-1-tosyl-2,3,4,5,6,7-hexahydro-1H-indol-7-yl)but-2-enoate, 14c

Note: a small amount of the Z-alkene ($E:Z \sim 20:1$) is observed ($J = 11.6$ Hz), in addition to the 13.5:1 ratio of diastereomers from the cycloaddition.


^1H NMR (400 MHz, CDCl_3)



140




¹³C NMR (101 MHz, CDCl₃)




(E)-Ethyl 4-((5S,6S,7R)-6-nitro-1-tosyl-5-(4-(trifluoromethyl)phenyl)-2,3,4,5,6,7-hexahydro-1H-indol-7-yl)but-2-enoate, 14d

Note: a small amount of the Z-alkene (*E*:*Z* ~ 20:1) is observed (*J* = 11.6 Hz), in addition to the 8:1 ratio of diastereomers from the cycloaddition.

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-Ethyl 4-((5S,6S,7R)-5-(4-methoxyphenyl)-6-nitro-1-tosyl-2,3,4,5,6,7-hexahydro-1H-indol-7-yl)but-2-enoate, 14e

Note: a small amount of the Z-alkene ($E:Z \sim 30:1$) is observed ($J = 11.6$ Hz), but no diastereomer from the cycloaddition could be detected.

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




(E)-Ethyl 4-((5*R*,6*R*,7*R*)-5-(furan-2-yl)-6-nitro-1-tosyl-2,3,4,5,6,7-hexahydro-1*H*-indol-7-yl)but-2-enoate, 14f



Note: a small amount of the Z-alkene (*E*:*Z* ~ 20:1) is observed (*J* = 11.6 Hz), in addition to the 9:1 ratio of diastereomers from the cycloaddition.

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)






(E)-Ethyl 4-((4'R,5S,7R)-5'-oxo-2',5-diphenyl-1-tosyl-1,2,3,4,5,7-hexahydro-5'H-spiro[indole-6,4'-oxazol]-7-yl)but-2-enoate, 16a

¹H NMR (400 MHz, CDCl₃)





¹³C NMR (101 MHz, CDCl₃)




(E)-Ethyl 4-((4'R,5S,7R)-5-(4-bromophenyl)-5'-oxo-2'-phenyl-1-tosyl-1,2,3,4,5,7-hexahydro-5'H-spiro[indole-6,4'-oxazol]-7-yl)but-2-enoate, 16b

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)





(E)-Ethyl 4-((4'R,5S,7R)-5-(4-methoxyphenyl)-5'-oxo-2'-phenyl-1-tosyl-1,2,3,4,5,7-hexahydro-5'H-spiro[indole-6,4'-oxazol]-7-yl)but-2-enoate, 16c

¹H NMR (400 MHz, CDCl₃)



¹³C NMR (101 MHz, CDCl₃)







3.3 Intermediates in the synthesis of dienals **4a-d and **8a****

(E)-Methyl (6-((tert-butyldimethylsilyl)oxy)hex-3-en-1-yl)(tosyl)carbamate, S6

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-N-(6-((tert-butyldimethylsilyl)oxy)hex-3-en-1-yl)-4-methylbenzenesulfonamide, S7

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




(E)-N-(6-((tert-Butyldimethylsilyl)oxy)hex-3-en-1-yl)-4-methyl-N-(oct-1-yn-1-yl)benzenesulfonamide, 5b

¹H NMR (400 MHz, CDCl₃)





¹³C NMR (101 MHz, CDCl₃)




(Z)-3-((E)-3-((tert-butyldimethylsilyl)oxy)prop-1-en-1-yl)-2-heptylidene-1-tosylpyrrolidine, S8a

^1H NMR (400 MHz, CDCl_3)




¹³C NMR (101 MHz, CDCl₃)




(E)-3-((Z)-2-heptylidene-1-tosylpyrrolidin-3-yl)prop-2-en-1-ol, S9a

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-3-((*Z*)-2-heptylidene-1-tosylpyrrolidin-3-yl)acrylaldehyde, 4a

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-3-(2-heptyl-1-tosyl-4,5-dihydro-1H-pyrrol-3-yl)acrylaldehyde, 8a

¹H NMR (400 MHz, CDCl₃)





¹³C NMR (101 MHz, CDCl₃)




(E)-N-(6-((tert-Butyldimethylsilyl)oxy)hex-3-en-1-yl)-N-(5-chloropent-1-yn-1-yl)-4-ethylbenzenesulfonamide, 5c

^1H NMR (400 MHz, CDCl_3)




¹³C NMR (101 MHz, CDCl₃)




(Z)-3-((E)-3-((tert-Butyldimethylsilyl)oxy)prop-1-en-1-yl)-2-(4-chlorobutylidene)-1-tosylpyrrolidine, S8b

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-3-((Z)-2-(4-Chlorobutylidene)-1-tosylpyrrolidin-3-yl)prop-2-en-1-ol, S9b

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-3-((Z)-2-(4-chlorobutylidene)-1-tosylpyrrolidin-3-yl)acrylaldehyde, 4b

¹H NMR (400 MHz, CDCl₃)





¹³C NMR (101 MHz, CDCl₃)




(E)-N-(6-((tert-Butyldimethylsilyl)oxy)hex-3-en-1-yl)-4-methyl-N-(prop-1-yn-1-yl)benzenesulfonamide, 5d

^1H NMR (400 MHz, CDCl_3)




¹³CNMR (101 MHz, CDCl₃)




(Z)-3-((E)-3-((tert-Butyldimethylsilyl)oxy)prop-1-en-1-yl)-2-ethylidene-1-tosylpyrrolidine, S8c

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-3-((Z)-2-Ethylidene-1-tosylpyrrolidin-3-yl)prop-2-en-1-ol, S9c

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-3-((Z)-2-Ethylidene-1-tosylpyrrolidin-3-yl)acrylaldehyde, 4c

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-N-(6-((tert-Butyldimethylsilyl)oxy)hex-3-en-1-yl)-4-methyl-N-(phenylethyynyl)benzenesulfonamide, 5e

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(Z)-2-Benzylidene-3-((E)-3-((tert-butyldimethylsilyl)oxy)prop-1-en-1-yl)-1-tosylpyrrolidine, S8d

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-3-((Z)-2-Benzylidene-1-tosylpyrrolidin-3-yl)prop-2-en-1-ol, S9d

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(E)-3-((*Z*)-2-benzylidene-1-tosylpyrrolidin-3-yl)acrylaldehyde, 4d

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




1.3.4 Cycloaddition reactions of dienals **4a-d**

(*3'S,4S,6S,7S*)-1'-*tert*-Butyl 6-ethyl 7-hexyl-2'-oxo-4-(2-oxoethyl)-1-tosyl-1,2,3,4,6,7-hexahydrospiro[indole-5,3'-indoline]-1',6-dicarboxylate, **12a**

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(3'S,4S,6S,7S)-1'-*tert*-Butyl 6-ethyl 7-(3-chloropropyl)-2'-oxo-4-(2-oxoethyl)-1-tosyl-1,2,3,4,6,7-hexahydrospiro[indole-5,3'-indoline]-1',6-dicarboxylate, 12b

^1H NMR (500 MHz, CDCl_3)




^{13}C NMR (125 MHz, CDCl_3)






(3'S,4S,6S,7S)-1'-*tert*-Butyl 6-ethyl 7-methyl-2'-oxo-4-(2-oxoethyl)-1-tosyl-1,2,3,4,6,7-hexahydrospiro[indole-5,3'-indoline]-1',6-dicarboxylate, 12c

^1H NMR (500 MHz, CDCl_3)





^{13}C NMR (125 MHz, CDCl_3)






(3'S,4S,6S,7R)-1'-*tert*-Butyl 6-ethyl 2'-oxo-4-(2-oxoethyl)-7-phenyl-1-tosyl-1,2,3,4,6,7-hexahydrospiro[indole-5,3'-indoline]-1',6-dicarboxylate, 12d

^1H NMR (400 MHz, CDCl_3)





¹³C NMR (101 MHz, CDCl₃)




(3'S,4S,6S,7S)-1'-*tert*-Butyl 6-ethyl 5'-chloro-7-hexyl-2'-oxo-4-(2-oxoethyl)-1-tosyl-1,2,3,4,6,7-hexahydrospiro[indole-5,3'-indoline]-1',6-dicarboxylate, 12e

^1H NMR (400 MHz, CDCl_3)




¹³C NMR (101 MHz, CDCl₃)




(3'S,4S,6S,7S)-1'-*tert*-Butyl 6-ethyl 7-hexyl-5'-methoxy-2'-oxo-4-(2-oxoethyl)-1-tosyl-1,2,3,4,6,7-hexahydrospiro[indole-5,3'-indoline]-1',6-dicarboxylate, 12f

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




(3'S,4S,6S,7S)-di-*tert*-Butyl 7-methyl-2'-oxo-4-(2-oxoethyl)-1-tosyl-1,2,3,4,6,7-hexahydrospiro[indole-5,3'-indoline]-1',6-dicarboxylate, 12g

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




(*3S,4'S,6'S,7'S*)- and (*3R,4'S,6'R,7'S*)-Ethyl 7'-methyl-2-oxo-4'-(2-oxoethyl)-1'-tosyl-1',2',3',4',6',7'-hexahydro-2H-spiro[benzofuran-3,5'-indole]-6'-carboxylate, **18a** and **18b**

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




3.5 Synthesis of dienals **3b** and **4e**

(*S*)-2-phenylbut-3-en-1-ol, **S10**

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(S)-methyl (2-phenylbut-3-en-1-yl)(tosyl)carbamate, S11

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(S)-N-(4-((tert-butyldimethylsilyl)oxy)but-1-yn-1-yl)-4-methyl-N-(2-phenylbut-3-en-1-yl)benzenesulfonamide, 5f

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(*R,Z*)-2-((*tert*-butyldimethylsilyl)oxy)propylidene)-3-methylene-4-phenyl-1-tosylpyrrolidine, S13

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(R,Z)-3-(3-methylene-4-phenyl-1-tosylpyrrolidin-2-ylidene)propan-1-ol, S14

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(*R,E*)-3-(3-methyl-4-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrrol-2-yl)acrylaldehyde, 3b

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




5-((*tert*-Butyldimethylsilyl)oxy)-1-phenylpent-1-yn-3-ol, S16

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




5-((*tert*-Butyldimethylsilyl)oxy)-1-phenylpent-1-yn-3-one, S17

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(S,E)-5-((tert-butyldimethylsilyl)oxy)-1-phenylpent-1-en-3-ol, S18

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(S,E)-5-((tert-Butyldimethylsilyl)oxy)-1-phenylpent-1-en-3-yl propionate, S19

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(2*R*,3*R*,*E*)-7-((*tert*-Butyldimethylsilyl)oxy)-2-methyl-3-phenylhept-4-enoic acid, S20

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




N-((2*R*,3*S*,*E*)-7-((tert-Butyldimethylsilyl)oxy)-3-phenylhept-4-en-2-yl)-4-methylbenzenesulfonamide, S21

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




N-((2*R*,3*S*,*E*)-7-((tert-Butyldimethylsilyl)oxy)-3-phenylhept-4-en-2-yl)-4-methyl-N-(prop-1-yn-1-yl)benzenesulfonamide, 5g

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




(3*R*,4*S*,5*R*,*Z*)-3-((*E*)-3-((tert-butyldimethylsilyl)oxy)prop-1-en-1-yl)-2-ethylidene-5-methyl-4-phenyl-1-tosylpyrrolidine, S22

¹H NMR (500 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




*(E)-3-((4*S*,5*R*,*Z*)-2-ethylidene-5-methyl-4-phenyl-1-tosylpyrrolidin-3-yl)prop-2-en-1-ol, S23*

¹H NMR (500 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)




*(E)-3-((4*S*,5*R*,*Z*)-2-ethylidene-5-methyl-4-phenyl-1-tosylpyrrolidin-3-yl)acrylaldehyde, 4e*

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




3.6 Double stereodifferentiating cycloaddition reactions of dienals **3b and **4e****



2-((3*R*,5*S*,6*S*,7*R*)-6-nitro-3,5-diphenyl-1-tosyl-2,3,4,5,6,7-hexahydro-1*H*-indol-7-yl)acetaldehyde, **19a**

¹H NMR (500 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)







2-(*(3R,5R,6R,7S*)-6-nitro-3,5-diphenyl-1-tosyl-2,3,4,5,6,7-hexahydro-1*H*-indol-7-yl)acetaldehyde, 19b

¹H NMR (500 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)








(3*R*,3'*S*,5*S*,7*R*)-1'-*tert*-butyl 5-ethyl 2'-oxo-7-(2-oxoethyl)-3-phenyl-1-tosyl-1,2,3,4,5,7-hexahydrospiro[indole-6,3'-indoline]-1',5-dicarboxylate, 11e

¹H NMR (500 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)









(3*R*,3'*R*,5*R*,7*S*)-1'-*tert*-butyl 5-ethyl 2'-oxo-7-(2-oxoethyl)-3-phenyl-1-tosyl-1,2,3,4,5,7-hexahydrospiro[indole-6,3'-indoline]-1',5-dicarboxylate, 11f

¹H NMR (500 MHz, CDCl₃)




¹³C NMR (125 MHz, CDCl₃)








(2*R*,3*R*,3'S,4*S*,6*S*,7*S*)-1'-*tert*-Butyl 6-ethyl 2,7-dimethyl-2'-oxo-4-(2-oxoethyl)-3-phenyl-1-tosyl-1,2,3,4,6,7-hexahydrospiro[indole-5,3'-indoline]-1',6-dicarboxylate, 12h

¹H NMR (500 MHz, CDCl₃)



¹³C NMR (125 MHz, CDCl₃)







(*2R,3R,3'R,4R,6R,7R*)-1'-*tert*-Butyl
dicarboxylate, 12i

6-ethyl

2,7-dimethyl-2'-oxo-4-(2-oxoethyl)-3-phenyl-1-tosyl-1,2,3,4,6,7-hexahydrospiro[indole-5,3'-indoline]-1',6-

¹H NMR (500 MHz, CDCl₃)



12i

¹³C NMR (125 MHz, CDCl₃)

